_MEMBER_att_D_no_prior_0 - 1.8-2.2,_MEMBER_att_D_no_prior_0 - 4.5-5.5,_MEMBER_att_D_no_prior_0 - 9.0-11.0,_LogP_att_D_no_prior_0 - 1.8-2.2,_LogP_att_D_no_prior_0 - 4.5-5.5,_LogP_att_D_no_prior_0 - 9.0-11.0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,-10,-11,-3,GO:0001775,cell activation,M111,3,0
1,1,1,-16,-9.1,-4.6,GO:0030097,hemopoiesis,M111,3,0
1,1,1,-8.8,-6.3,-5.4,GO:0030099,myeloid cell differentiation,M111,3,0
1,1,1,-9.3,-4.9,-3.3,GO:0030098,lymphocyte differentiation,M111,3,0
1,1,1,-3.5,-2.5,-5.1,GO:0002062,chondrocyte differentiation,M111,3,0
1,1,1,-4.7,-2.5,-2.2,GO:0030218,erythrocyte differentiation,M111,3,0
1,1,1,-3.5,-2.1,-3.6,M2,PID SMAD2 3NUCLEAR PATHWAY,M111,3,0
1,1,1,-3.8,-6.4,-2.1,GO:0042113,B cell activation,M111,3,0
1,1,1,-3.7,-7.3,-2.1,R-HSA-1280215,Cytokine Signaling in Immune system,M111,3,0
1,1,1,-8.8,-4.2,-2.3,WP2849,Hematopoietic stem cell differentiation,M111,3,0
1,1,1,-4.3,-2.4,-4.6,GO:0061448,connective tissue development,M111,3,0
1,1,1,-10,-7.1,-3,GO:1903131,mononuclear cell differentiation,M111,3,0
1,1,1,-6.2,-2.3,-3.8,R-HSA-9616222,Transcriptional regulation of granulopoiesis,M111,3,0
1,1,1,-12,-9.3,-3.7,GO:0046649,lymphocyte activation,M111,3,0
1,1,1,-12,-7.7,-3.1,GO:0002521,leukocyte differentiation,M111,3,0
1,1,1,-5.1,-2.3,-2.1,GO:0034101,erythrocyte homeostasis,M111,3,0
1,1,1,-5,-2.9,-2.1,GO:0070848,response to growth factor,M111,3,0
1,1,1,-3.3,-2.8,-5.4,GO:0051216,cartilage development,M111,3,0
1,1,1,-2.3,-2.4,-2.4,R-HSA-9006931,Signaling by Nuclear Receptors,M111,3,0
1,1,1,-5.1,-3.3,-2.3,hsa05202,Transcriptional misregulation in cancer,M111,3,0
1,1,1,-12,-12,-3,GO:0045321,leukocyte activation,M111,3,0
1,1,1,-3.6,-2.1,-2.2,GO:0071363,cellular response to growth factor stimulus,M111,3,0
1,1,1,-2.5,-4.6,-3.5,GO:0001501,skeletal system development,M111,3,0
1,1,0,-6.2,-3.7,0,GO:0002250,adaptive immune response,M110,2,0
1,1,0,-4.3,-5.7,0,GO:0050727,regulation of inflammatory response,M110,2,0
1,1,0,-2.6,-2.1,0,GO:0002244,hematopoietic progenitor cell differentiation,M110,2,0
1,1,0,-4.7,-2.6,0,GO:0002700,regulation of production of molecular mediator of immune response,M110,2,0
1,1,0,-2.2,-2.5,0,WP1541,Energy metabolism,M110,2,0
1,1,0,-2.6,-3.1,0,GO:0045937,positive regulation of phosphate metabolic process,M110,2,0
1,1,0,-3.6,-3.1,0,GO:2000147,positive regulation of cell motility,M110,2,0
1,1,0,-3.7,-2.3,0,GO:0002720,positive regulation of cytokine production involved in immune response,M110,2,0
1,1,0,-3.7,-2.8,0,WP437,EGF EGFR signaling pathway,M110,2,0
1,1,0,-3.4,-5.6,0,GO:2000377,regulation of reactive oxygen species metabolic process,M110,2,0
1,1,0,-5.4,-4.4,0,R-HSA-1280218,Adaptive Immune System,M110,2,0
1,1,0,-2.6,-2.5,0,R-HSA-3858494,Beta-catenin independent WNT signaling,M110,2,0
1,1,0,-4.5,-2.9,0,GO:0002699,positive regulation of immune effector process,M110,2,0
1,1,0,-3.8,-2.2,0,R-HSA-451927,Interleukin-2 family signaling,M110,2,0
1,1,0,-2.3,-5.2,0,GO:0045785,positive regulation of cell adhesion,M110,2,0
1,1,0,-3.6,-7.7,0,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M110,2,0
1,1,0,-3.2,-6.4,0,GO:0070665,positive regulation of leukocyte proliferation,M110,2,0
1,1,0,-7.9,-3.5,0,GO:0045637,regulation of myeloid cell differentiation,M110,2,0
1,0,1,-4.9,0,-3.3,GO:0072089,stem cell proliferation,M101,2,0
1,1,0,-2.7,-3.4,0,hsa05210,Colorectal cancer,M110,2,0
1,1,0,-4.9,-2.4,0,WP2882,Nuclear receptors meta pathway,M110,2,0
1,1,0,-3.1,-3.2,0,GO:0045648,positive regulation of erythrocyte differentiation,M110,2,0
1,1,0,-4.7,-5,0,GO:0070663,regulation of leukocyte proliferation,M110,2,0
1,1,0,-3.4,-3.1,0,GO:1901342,regulation of vasculature development,M110,2,0
1,1,0,-2.1,-2.9,0,GO:0042832,defense response to protozoan,M110,2,0
1,1,0,-2,-2.5,0,M223,PID BETA CATENIN NUC PATHWAY,M110,2,0
1,1,0,-8.8,-3.9,0,hsa05166,Human T-cell leukemia virus 1 infection,M110,2,0
1,1,0,-2.4,-3.3,0,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M110,2,0
1,1,0,-4.7,-6,0,GO:0002573,myeloid leukocyte differentiation,M110,2,0
1,1,0,-3,-3.3,0,GO:0002822,regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M110,2,0
1,1,0,-6.6,-2.9,0,GO:2000107,negative regulation of leukocyte apoptotic process,M110,2,0
1,1,0,-6.4,-2.9,0,GO:0006897,endocytosis,M110,2,0
1,1,0,-4.5,-6.1,0,GO:1902107,positive regulation of leukocyte differentiation,M110,2,0
1,1,0,-3.1,-2.8,0,GO:0045765,regulation of angiogenesis,M110,2,0
1,1,0,-4.4,-4.5,0,GO:0050670,regulation of lymphocyte proliferation,M110,2,0
1,1,0,-3.4,-4,0,GO:0050851,antigen receptor-mediated signaling pathway,M110,2,0
1,1,0,-5.4,-5.4,0,GO:0002757,immune response-activating signaling pathway,M110,2,0
1,1,0,-2.1,-4.4,0,GO:1903557,positive regulation of tumor necrosis factor superfamily cytokine production,M110,2,0
1,1,0,-4.7,-4.9,0,GO:0002263,cell activation involved in immune response,M110,2,0
1,1,0,-3.6,-5.1,0,hsa04380,Osteoclast differentiation,M110,2,0
1,1,0,-2.7,-2.4,0,WP2877,Vitamin D receptor pathway,M110,2,0
1,1,0,-2,-2,0,GO:0002218,activation of innate immune response,M110,2,0
1,1,0,-4.2,-6.7,0,GO:0022409,positive regulation of cell-cell adhesion,M110,2,0
1,0,1,-2.5,0,-4.9,R-HSA-975577,N-Glycan antennae elongation,M101,2,0
1,1,0,-2.4,-3.2,0,GO:0002824,positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M110,2,0
1,1,0,-3.7,-3.1,0,WP366,TGF beta signaling pathway,M110,2,0
1,0,1,-3.8,0,-2.4,GO:0045165,cell fate commitment,M101,2,0
1,1,0,-3.2,-4.7,0,GO:0050728,negative regulation of inflammatory response,M110,2,0
1,1,0,-4.2,-3.2,0,GO:2000628,regulation of miRNA metabolic process,M110,2,0
1,1,0,-3,-2.4,0,hsa05169,Epstein-Barr virus infection,M110,2,0
1,1,0,-4.3,-3.2,0,GO:0045646,regulation of erythrocyte differentiation,M110,2,0
1,1,0,-3.3,-5.2,0,GO:2000514,"regulation of CD4-positive, alpha-beta T cell activation",M110,2,0
1,1,0,-3.9,-2.1,0,GO:0002763,positive regulation of myeloid leukocyte differentiation,M110,2,0
1,1,0,-4.9,-3.8,0,GO:0032102,negative regulation of response to external stimulus,M110,2,0
1,1,0,-3.5,-3,0,GO:0040017,positive regulation of locomotion,M110,2,0
1,1,0,-2.4,-5.1,0,hsa05152,Tuberculosis,M110,2,0
1,1,0,-5.1,-5.3,0,GO:0002252,immune effector process,M110,2,0
1,1,0,-4.7,-3.7,0,WP363,Wnt signaling pathway,M110,2,0
1,1,0,-2.7,-2.6,0,GO:0001910,regulation of leukocyte mediated cytotoxicity,M110,2,0
1,1,0,-3.2,-2.5,0,GO:0002698,negative regulation of immune effector process,M110,2,0
1,1,0,-5.5,-2.8,0,GO:0009617,response to bacterium,M110,2,0
1,1,0,-4.4,-2,0,GO:0010863,positive regulation of phospholipase C activity,M110,2,0
1,1,0,-6.6,-5.6,0,GO:0010720,positive regulation of cell development,M110,2,0
1,1,0,-8.1,-6.1,0,GO:0042110,T cell activation,M110,2,0
1,1,0,-2.3,-3.6,0,GO:0002443,leukocyte mediated immunity,M110,2,0
1,1,0,-2.5,-3.1,0,GO:0002704,negative regulation of leukocyte mediated immunity,M110,2,0
1,1,0,-3.2,-4.4,0,GO:0050777,negative regulation of immune response,M110,2,0
1,1,0,-2.8,-2.2,0,GO:0002706,regulation of lymphocyte mediated immunity,M110,2,0
1,1,0,-4.5,-3.2,0,GO:1903038,negative regulation of leukocyte cell-cell adhesion,M110,2,0
1,1,0,-5.2,-5.4,0,GO:0002764,immune response-regulating signaling pathway,M110,2,0
1,1,0,-5,-4.2,0,WP5293,Acute myeloid leukemia,M110,2,0
1,1,0,-2.4,-2.1,0,GO:0071560,cellular response to transforming growth factor beta stimulus,M110,2,0
1,1,0,-2.8,-2.4,0,WP2840,Hair follicle development cytodifferentiation part 3 of 3,M110,2,0
1,1,0,-3.2,-4,0,WP560,TGF beta receptor signaling,M110,2,0
1,0,1,-3.5,0,-3.3,R-HSA-8878171,Transcriptional regulation by RUNX1,M101,2,0
1,1,0,-2.5,-2,0,R-HSA-187037,Signaling by NTRK1 (TRKA),M110,2,0
1,1,0,-3.6,-5.9,0,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M110,2,0
1,1,0,-3.3,-2.5,0,hsa05323,Rheumatoid arthritis,M110,2,0
1,1,0,-4.6,-3,0,GO:0002695,negative regulation of leukocyte activation,M110,2,0
1,1,0,-3.1,-3.9,0,WP4816,TGF beta receptor signaling in skeletal dysplasias,M110,2,0
1,1,0,-2.6,-2.3,0,GO:0002827,positive regulation of T-helper 1 type immune response,M110,2,0
1,1,0,-2.7,-2.6,0,GO:0071559,response to transforming growth factor beta,M110,2,0
1,1,0,-3.7,-2.2,0,GO:0045088,regulation of innate immune response,M110,2,0
1,1,0,-2.4,-4.4,0,GO:0060326,cell chemotaxis,M110,2,0
1,1,0,-2.6,-2.5,0,R-HSA-5621481,C-type lectin receptors (CLRs),M110,2,0
1,1,0,-2.4,-2.4,0,WP5036,Angiotensin II receptor type 1 pathway,M110,2,0
1,1,0,-2,-6.8,0,GO:0045582,positive regulation of T cell differentiation,M110,2,0
1,1,0,-5.9,-3.3,0,GO:2000106,regulation of leukocyte apoptotic process,M110,2,0
1,1,0,-3.1,-3.8,0,GO:0051345,positive regulation of hydrolase activity,M110,2,0
1,1,0,-2.8,-3.7,0,R-HSA-8951430,RUNX3 regulates WNT signaling,M110,2,0
1,1,0,-4,-4.9,0,GO:0002703,regulation of leukocyte mediated immunity,M110,2,0
1,1,0,-5.5,-2.1,0,GO:0002286,T cell activation involved in immune response,M110,2,0
1,1,0,-2.1,-3.1,0,GO:0097305,response to alcohol,M110,2,0
1,1,0,-2.9,-4.4,0,GO:2000379,positive regulation of reactive oxygen species metabolic process,M110,2,0
1,1,0,-2.6,-2.3,0,hsa05133,Pertussis,M110,2,0
1,1,0,-2.4,-3.7,0,hsa05132,Salmonella infection,M110,2,0
1,1,0,-4.2,-2.4,0,GO:0002825,regulation of T-helper 1 type immune response,M110,2,0
1,1,0,-4.6,-5.9,0,GO:0031348,negative regulation of defense response,M110,2,0
1,1,0,-3.7,-2.8,0,GO:2000630,positive regulation of miRNA metabolic process,M110,2,0
1,1,0,-6.4,-7.3,0,GO:0050867,positive regulation of cell activation,M110,2,0
0,1,1,0,-2.6,-3.1,R-HSA-8939211,ESR-mediated signaling,M011,2,0
1,1,0,-3.4,-4,0,GO:0001818,negative regulation of cytokine production,M110,2,0
1,1,0,-6.5,-2.7,0,GO:0030217,T cell differentiation,M110,2,0
1,1,0,-4.4,-6.8,0,GO:0002429,immune response-activating cell surface receptor signaling pathway,M110,2,0
1,1,0,-2.1,-3.7,0,WP3929,Chemokine signaling pathway,M110,2,0
1,1,0,-2.2,-3.5,0,GO:0030888,regulation of B cell proliferation,M110,2,0
1,1,0,-7.4,-5.1,0,GO:0045639,positive regulation of myeloid cell differentiation,M110,2,0
1,1,0,-4.5,-2.4,0,GO:0051090,regulation of DNA-binding transcription factor activity,M110,2,0
1,1,0,-3.7,-3.5,0,hsa04650,Natural killer cell mediated cytotoxicity,M110,2,0
1,0,1,-5.4,0,-3,GO:0008283,cell population proliferation,M101,2,0
1,1,0,-8.9,-7.6,0,GO:0051249,regulation of lymphocyte activation,M110,2,0
1,1,0,-2.7,-3.5,0,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M110,2,0
1,1,0,-4.7,-4.9,0,GO:0002366,leukocyte activation involved in immune response,M110,2,0
1,1,0,-3.5,-2,0,GO:0070229,negative regulation of lymphocyte apoptotic process,M110,2,0
1,1,0,-2.6,-3.1,0,GO:0010562,positive regulation of phosphorus metabolic process,M110,2,0
1,1,0,-2.2,-3.4,0,GO:0030101,natural killer cell activation,M110,2,0
1,1,0,-6.9,-5.8,0,GO:0001819,positive regulation of cytokine production,M110,2,0
1,1,0,-7.2,-7.7,0,GO:0006954,inflammatory response,M110,2,0
1,0,1,-2.1,0,-2.6,R-HSA-948021,Transport to the Golgi and subsequent modification,M101,2,0
1,1,0,-3.5,-4.1,0,M7,PID FCER1 PATHWAY,M110,2,0
1,1,0,-4.5,-6.8,0,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M110,2,0
1,1,0,-3.1,-2.6,0,hsa05211,Renal cell carcinoma,M110,2,0
1,1,0,-6,-3.9,0,GO:0002683,negative regulation of immune system process,M110,2,0
1,1,0,-5.7,-8.4,0,GO:1903037,regulation of leukocyte cell-cell adhesion,M110,2,0
1,1,0,-2.2,-2.5,0,GO:0045622,regulation of T-helper cell differentiation,M110,2,0
1,1,0,-2.2,-3,0,GO:0032928,regulation of superoxide anion generation,M110,2,0
1,1,0,-2.4,-3.6,0,R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,M110,2,0
1,1,0,-2.8,-3.1,0,GO:0002821,positive regulation of adaptive immune response,M110,2,0
1,1,0,-2.4,-2.6,0,WP3932,Focal adhesion PI3K Akt mTOR signaling pathway,M110,2,0
1,1,0,-2.3,-2.6,0,GO:0071248,cellular response to metal ion,M110,2,0
1,0,1,-3.9,0,-2.1,GO:0006351,DNA-templated transcription,M101,2,0
1,1,0,-2.6,-4.6,0,GO:0050671,positive regulation of lymphocyte proliferation,M110,2,0
1,1,0,-5.1,-4.3,0,hsa05221,Acute myeloid leukemia,M110,2,0
1,1,0,-2.1,-3.3,0,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M110,2,0
1,1,0,-2.9,-4.8,0,GO:0030183,B cell differentiation,M110,2,0
1,1,0,-3.2,-3.2,0,GO:0050871,positive regulation of B cell activation,M110,2,0
1,1,0,-2.3,-3.7,0,hsa04613,Neutrophil extracellular trap formation,M110,2,0
1,1,0,-5.1,-2.4,0,GO:0051250,negative regulation of lymphocyte activation,M110,2,0
1,1,0,-8.5,-7.9,0,GO:0002694,regulation of leukocyte activation,M110,2,0
1,1,0,-4.5,-6.1,0,GO:1903708,positive regulation of hemopoiesis,M110,2,0
1,1,0,-2.1,-3.4,0,GO:0007264,small GTPase mediated signal transduction,M110,2,0
1,1,0,-2.5,-2.2,0,WP4336,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,M110,2,0
1,1,0,-2.7,-4.2,0,GO:0043370,"regulation of CD4-positive, alpha-beta T cell differentiation",M110,2,0
1,1,0,-2.9,-3.1,0,WP3863,T cell antigen receptor TCR pathway during Staphylococcus aureus infection,M110,2,0
1,1,0,-3.4,-2.2,0,WP5130,Th17 cell differentiation pathway,M110,2,0
1,1,0,-3.7,-5.8,0,WP23,B cell receptor signaling pathway,M110,2,0
1,1,0,-2.4,-3.8,0,GO:0050900,leukocyte migration,M110,2,0
1,1,0,-3.4,-2.6,0,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M110,2,0
0,1,1,0,-3.2,-2.8,GO:0120031,plasma membrane bounded cell projection assembly,M011,2,0
1,1,0,-8.2,-6.6,0,GO:0050865,regulation of cell activation,M110,2,0
1,0,1,-2.4,0,-2.9,R-HSA-9018519,Estrogen-dependent gene expression,M101,2,0
1,1,0,-5.4,-5.5,0,GO:0071345,cellular response to cytokine stimulus,M110,2,0
1,1,0,-6.2,-7,0,GO:0050863,regulation of T cell activation,M110,2,0
1,1,0,-2.1,-3.7,0,hsa04928,"Parathyroid hormone synthesis, secretion and action",M110,2,0
1,1,0,-3.3,-3,0,GO:0002702,positive regulation of production of molecular mediator of immune response,M110,2,0
0,1,1,0,-2.4,-2.1,GO:0120035,regulation of plasma membrane bounded cell projection organization,M011,2,0
1,1,0,-2.9,-3.7,0,GO:0031341,regulation of cell killing,M110,2,0
1,1,0,-2.3,-2,0,WP4018,Clear cell renal cell carcinoma pathways,M110,2,0
1,1,0,-3.7,-2.7,0,GO:0042742,defense response to bacterium,M110,2,0
1,0,1,-3.1,0,-4.4,R-HSA-975576,N-glycan antennae elongation in the medial/trans-Golgi,M101,2,0
1,1,0,-2.3,-2.6,0,GO:0031343,positive regulation of cell killing,M110,2,0
1,1,0,-6.2,-7.3,0,GO:0051251,positive regulation of lymphocyte activation,M110,2,0
1,1,0,-3.7,-2,0,WP399,Wnt signaling pathway and pluripotency,M110,2,0
1,1,0,-5.8,-4.5,0,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M110,2,0
1,1,0,-3.6,-3.4,0,GO:0019221,cytokine-mediated signaling pathway,M110,2,0
1,1,0,-3.4,-2.5,0,WP4205,MET in type 1 papillary renal cell carcinoma,M110,2,0
1,1,0,-4.8,-2.1,0,GO:0050868,negative regulation of T cell activation,M110,2,0
1,1,0,-2.2,-3,0,R-HSA-8878159,Transcriptional regulation by RUNX3,M110,2,0
1,1,0,-3.4,-8.5,0,R-HSA-449147,Signaling by Interleukins,M110,2,0
1,1,0,-4.1,-3.6,0,GO:0002819,regulation of adaptive immune response,M110,2,0
1,1,0,-3.7,-6.9,0,GO:0045621,positive regulation of lymphocyte differentiation,M110,2,0
1,1,0,-2.4,-3.2,0,GO:0032930,positive regulation of superoxide anion generation,M110,2,0
1,1,0,-3.4,-6.4,0,GO:0050870,positive regulation of T cell activation,M110,2,0
1,1,0,-3.1,-4,0,R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,M110,2,0
1,0,1,-2.2,0,-4.6,R-HSA-8951936,RUNX3 regulates p14-ARF,M101,2,0
1,1,0,-2.5,-3.8,0,M10,PID BCR 5PATHWAY,M110,2,0
1,1,0,-2.8,-2.7,0,M22,PID GMCSF PATHWAY,M110,2,0
1,1,0,-2.5,-2.8,0,GO:0032680,regulation of tumor necrosis factor production,M110,2,0
1,1,0,-2.9,-3,0,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M110,2,0
1,1,0,-3,-2.1,0,hsa05226,Gastric cancer,M110,2,0
1,0,1,-3.1,0,-4.4,WP5153,N glycan biosynthesis,M101,2,0
1,1,0,-3.1,-5.8,0,GO:0046637,regulation of alpha-beta T cell differentiation,M110,2,0
1,1,0,-4.6,-2.4,0,GO:0050866,negative regulation of cell activation,M110,2,0
1,1,0,-2.2,-3.8,0,GO:1904018,positive regulation of vasculature development,M110,2,0
1,0,1,-4.2,0,-2.5,R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,M101,2,0
1,1,0,-6.6,-6.3,0,GO:0050778,positive regulation of immune response,M110,2,0
1,1,0,-2.5,-3.4,0,hsa04936,Alcoholic liver disease,M110,2,0
1,1,0,-4.3,-5.1,0,R-HSA-109582,Hemostasis,M110,2,0
1,1,0,-2.6,-2.3,0,GO:0007389,pattern specification process,M110,2,0
1,1,0,-5.1,-4.9,0,M186,PID PDGFRB PATHWAY,M110,2,0
1,1,0,-2.9,-2,0,GO:0071417,cellular response to organonitrogen compound,M110,2,0
1,0,1,-2.6,0,-4,hsa00510,N-Glycan biosynthesis,M101,2,0
1,1,0,-4.6,-3.5,0,GO:1902893,regulation of miRNA transcription,M110,2,0
1,1,0,-3.7,-2.8,0,GO:0002705,positive regulation of leukocyte mediated immunity,M110,2,0
1,1,0,-2.9,-2,0,WP4341,Non genomic actions of 1 25 dihydroxyvitamin D3,M110,2,0
1,1,0,-4.2,-3.2,0,GO:1902895,positive regulation of miRNA transcription,M110,2,0
1,1,0,-5,-2.6,0,GO:0009725,response to hormone,M110,2,0
1,1,0,-5.9,-5.9,0,GO:0022407,regulation of cell-cell adhesion,M110,2,0
1,1,0,-3,-5.2,0,GO:0032946,positive regulation of mononuclear cell proliferation,M110,2,0
0,1,1,0,-4.8,-2.6,GO:0030031,cell projection assembly,M011,2,0
1,1,0,-3.4,-3.9,0,hsa04660,T cell receptor signaling pathway,M110,2,0
1,1,0,-2.2,-2.8,0,R-HSA-912526,Interleukin receptor SHC signaling,M110,2,0
1,1,0,-2.5,-2.9,0,GO:0050864,regulation of B cell activation,M110,2,0
1,1,0,-4.1,-8.6,0,GO:0045580,regulation of T cell differentiation,M110,2,0
1,1,0,-3,-2.6,0,R-HSA-195721,Signaling by WNT,M110,2,0
1,1,0,-4.9,-5,0,GO:0032944,regulation of mononuclear cell proliferation,M110,2,0
1,1,0,-3.8,-2,0,hsa04658,Th1 and Th2 cell differentiation,M110,2,0
1,1,0,-3.1,-2.8,0,GO:0042129,regulation of T cell proliferation,M110,2,0
1,1,0,-2.5,-6.9,0,GO:0002274,myeloid leukocyte activation,M110,2,0
1,1,0,-4.4,-3.1,0,GO:0002285,lymphocyte activation involved in immune response,M110,2,0
1,1,0,-3.7,-2,0,WP75,Toll like receptor signaling pathway,M110,2,0
1,1,0,-3.1,-3.2,0,GO:0090322,regulation of superoxide metabolic process,M110,2,0
1,1,0,-6.4,-7.9,0,GO:0002696,positive regulation of leukocyte activation,M110,2,0
1,1,0,-3.5,-3.2,0,GO:0032757,positive regulation of interleukin-8 production,M110,2,0
1,1,0,-3.4,-4.2,0,GO:0032677,regulation of interleukin-8 production,M110,2,0
1,1,0,-4,-3.3,0,R-HSA-202733,Cell surface interactions at the vascular wall,M110,2,0
0,1,1,0,-2.3,-2.1,GO:0031344,regulation of cell projection organization,M011,2,0
1,0,1,-3.8,0,-2.1,GO:0032774,RNA biosynthetic process,M101,2,0
1,1,0,-2.7,-2.6,0,R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,M110,2,0
1,1,0,-2.7,-2,0,R-HSA-4086398,Ca2+ pathway,M110,2,0
1,1,0,-3.6,-3.2,0,WP2857,Mesodermal commitment pathway,M110,2,0
1,1,0,-2.8,-2.7,0,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M110,2,0
1,0,1,-3.2,0,-3.7,WP3892,Development of pulmonary dendritic cells and macrophage subsets,M101,2,0
1,1,0,-2.5,-2.4,0,GO:0071241,cellular response to inorganic substance,M110,2,0
1,1,0,-7,-4.8,0,hsa05200,Pathways in cancer,M110,2,0
1,1,0,-5.4,-2.9,0,GO:0046631,alpha-beta T cell activation,M110,2,0
1,1,0,-9.7,-8,0,GO:1903706,regulation of hemopoiesis,M110,2,0
1,1,0,-4.5,-4.8,0,GO:0002253,activation of immune response,M110,2,0
1,1,0,-2.2,-3.5,0,GO:0031667,response to nutrient levels,M110,2,0
1,1,0,-2.7,-2.3,0,hsa05225,Hepatocellular carcinoma,M110,2,0
1,1,0,-4.3,-6.8,0,GO:0002768,immune response-regulating cell surface receptor signaling pathway,M110,2,0
1,1,0,-7.6,-3.2,0,hsa04659,Th17 cell differentiation,M110,2,0
1,1,0,-2.1,-2.2,0,GO:0030900,forebrain development,M110,2,0
1,1,0,-2.4,-2.1,0,R-HSA-5607764,CLEC7A (Dectin-1) signaling,M110,2,0
1,1,0,-6.1,-2,0,GO:0002718,regulation of cytokine production involved in immune response,M110,2,0
1,1,0,-2,-2.6,0,GO:0021537,telencephalon development,M110,2,0
1,1,0,-3.3,-3.5,0,M255,PID HIF1 TFPATHWAY,M110,2,0
1,1,0,-5.7,-3.4,0,GO:0006909,phagocytosis,M110,2,0
1,1,0,-3.1,-2,0,M195,PID CMYB PATHWAY,M110,2,0
1,1,0,-7,-7.2,0,GO:1902105,regulation of leukocyte differentiation,M110,2,0
1,1,0,-2.1,-2.5,0,GO:0050730,regulation of peptidyl-tyrosine phosphorylation,M110,2,0
1,1,0,-2.4,-3.7,0,WP5098,T cell activation SARS CoV 2,M110,2,0
0,1,1,0,-9.5,-3.6,WP3945,TYROBP causal network in microglia,M011,2,0
1,1,0,-3.5,-3.3,0,GO:0030335,positive regulation of cell migration,M110,2,0
1,1,0,-4.4,-3.4,0,GO:0140747,regulation of ncRNA transcription,M110,2,0
1,1,0,-6.3,-5.1,0,GO:0002697,regulation of immune effector process,M110,2,0
1,1,0,-6,-3.4,0,hsa05417,Lipid and atherosclerosis,M110,2,0
1,1,0,-2.4,-3.1,0,GO:0032675,regulation of interleukin-6 production,M110,2,0
1,1,0,-2.4,-4,0,GO:0009991,response to extracellular stimulus,M110,2,0
1,1,0,-5.2,-8.8,0,GO:0045619,regulation of lymphocyte differentiation,M110,2,0
1,1,0,-2.1,-2.2,0,R-HSA-2871809,FCERI mediated Ca+2 mobilization,M110,2,0
1,1,0,-2.8,-2.4,0,WP5094,Orexin receptor pathway,M110,2,0
1,1,0,-3.5,-6.7,0,GO:0046634,regulation of alpha-beta T cell activation,M110,2,0
1,1,0,-4.4,-6,0,WP286,IL 3 signaling pathway,M110,2,0
1,1,0,-4.3,-6,0,GO:0045087,innate immune response,M110,2,0
1,1,0,-8.2,-3.2,0,M167,PID AP1 PATHWAY,M110,2,0
1,1,0,-2.9,-2.7,0,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M110,2,0
1,0,1,-2.7,0,-2.6,GO:0061515,myeloid cell development,M101,2,0
1,1,0,-2.7,-2.3,0,R-HSA-201681,TCF dependent signaling in response to WNT,M110,2,0
1,1,0,-2.1,-3.7,0,GO:0032760,positive regulation of tumor necrosis factor production,M110,2,0
1,1,0,-3,-2.1,0,GO:0070228,regulation of lymphocyte apoptotic process,M110,2,0
0,1,0,0,-6.2,0,hsa04664,Fc epsilon RI signaling pathway,M010,1,0
0,1,0,0,-2.3,0,GO:0062042,regulation of cardiac epithelial to mesenchymal transition,M010,1,0
1,0,0,-2.2,0,0,R-HSA-9006335,Signaling by Erythropoietin,M100,1,0
1,0,0,-2.1,0,0,GO:0045589,regulation of regulatory T cell differentiation,M100,1,0
1,0,0,-4.1,0,0,GO:0001701,in utero embryonic development,M100,1,0
1,0,0,-2.4,0,0,GO:0048562,embryonic organ morphogenesis,M100,1,0
0,0,1,0,0,-2.4,GO:0031346,positive regulation of cell projection organization,M001,1,0
1,0,0,-3.1,0,0,WP4149,White fat cell differentiation,M100,1,0
1,0,0,-2.2,0,0,GO:1904746,negative regulation of apoptotic process involved in development,M100,1,0
1,0,0,-3.8,0,0,hsa04668,TNF signaling pathway,M100,1,0
1,0,0,-5.5,0,0,hsa04148,Efferocytosis,M100,1,0
1,0,0,-2.8,0,0,WP2873,Aryl hydrocarbon receptor pathway,M100,1,0
0,1,0,0,-3,0,GO:0018108,peptidyl-tyrosine phosphorylation,M010,1,0
0,1,0,0,-2.4,0,GO:0050729,positive regulation of inflammatory response,M010,1,0
1,0,0,-3.5,0,0,GO:2000736,regulation of stem cell differentiation,M100,1,0
1,0,0,-2.2,0,0,GO:0099172,presynapse organization,M100,1,0
1,0,0,-2.9,0,0,WP3931,Embryonic stem cell pluripotency pathways,M100,1,0
0,1,0,0,-5.1,0,R-HSA-9824443,Parasitic Infection Pathways,M010,1,0
0,1,0,0,-3.1,0,GO:0043378,"positive regulation of CD8-positive, alpha-beta T cell differentiation",M010,1,0
1,0,0,-2.2,0,0,GO:2000629,negative regulation of miRNA metabolic process,M100,1,0
1,0,0,-3.4,0,0,GO:0120161,regulation of cold-induced thermogenesis,M100,1,0
1,0,0,-2.4,0,0,GO:2000737,negative regulation of stem cell differentiation,M100,1,0
1,0,0,-2,0,0,GO:0097696,receptor signaling pathway via STAT,M100,1,0
0,1,0,0,-5.1,0,GO:0046641,positive regulation of alpha-beta T cell proliferation,M010,1,0
0,0,1,0,0,-3.1,WP474,Endochondral ossification,M001,1,0
1,0,0,-2.2,0,0,GO:0060397,growth hormone receptor signaling pathway via JAK-STAT,M100,1,0
1,0,0,-3.1,0,0,GO:0060068,vagina development,M100,1,0
1,0,0,-2.2,0,0,GO:1905459,regulation of vascular associated smooth muscle cell apoptotic process,M100,1,0
1,0,0,-3,0,0,GO:1902337,regulation of apoptotic process involved in morphogenesis,M100,1,0
0,0,1,0,0,-2.9,GO:0009100,glycoprotein metabolic process,M001,1,0
0,0,1,0,0,-2.7,GO:0051129,negative regulation of cellular component organization,M001,1,0
1,0,0,-3.5,0,0,GO:0048469,cell maturation,M100,1,0
1,0,0,-2.3,0,0,R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),M100,1,0
0,1,0,0,-2.8,0,GO:0017157,regulation of exocytosis,M010,1,0
1,0,0,-2.8,0,0,R-HSA-9670439,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",M100,1,0
0,1,0,0,-3.5,0,GO:1905007,positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation,M010,1,0
1,0,0,-4.7,0,0,GO:0071396,cellular response to lipid,M100,1,0
0,1,0,0,-2.1,0,GO:0051495,positive regulation of cytoskeleton organization,M010,1,0
0,1,0,0,-4,0,GO:0034341,response to type II interferon,M010,1,0
0,1,0,0,-3.6,0,GO:0002886,regulation of myeloid leukocyte mediated immunity,M010,1,0
0,1,0,0,-3,0,GO:0050731,positive regulation of peptidyl-tyrosine phosphorylation,M010,1,0
1,0,0,-3.4,0,0,GO:0060686,negative regulation of prostatic bud formation,M100,1,0
1,0,0,-2.3,0,0,R-HSA-1433557,Signaling by SCF-KIT,M100,1,0
1,0,0,-2.9,0,0,WP170,Nuclear receptors,M100,1,0
1,0,0,-2.1,0,0,GO:0043122,regulation of canonical NF-kappaB signal transduction,M100,1,0
0,1,0,0,-2.7,0,GO:0001562,response to protozoan,M010,1,0
0,1,0,0,-2.7,0,GO:0002220,innate immune response activating cell surface receptor signaling pathway,M010,1,0
1,0,0,-2.1,0,0,GO:0060537,muscle tissue development,M100,1,0
1,0,0,-2.5,0,0,GO:0048545,response to steroid hormone,M100,1,0
0,1,0,0,-2.6,0,GO:0030832,regulation of actin filament length,M010,1,0
0,1,0,0,-2.5,0,WP289,Myometrial relaxation and contraction pathways,M010,1,0
0,1,0,0,-2.4,0,GO:0001516,prostaglandin biosynthetic process,M010,1,0
1,0,0,-2.2,0,0,GO:0019883,antigen processing and presentation of endogenous antigen,M100,1,0
1,0,0,-3.9,0,0,WP4269,Ethanol metabolism production of ROS by CYP2E1,M100,1,0
0,0,1,0,0,-2.5,GO:0048705,skeletal system morphogenesis,M001,1,0
0,1,0,0,-4.8,0,GO:0045061,thymic T cell selection,M010,1,0
0,1,0,0,-3,0,GO:0030593,neutrophil chemotaxis,M010,1,0
1,0,0,-2.2,0,0,GO:0002711,positive regulation of T cell mediated immunity,M100,1,0
1,0,0,-2.1,0,0,GO:0007405,neuroblast proliferation,M100,1,0
1,0,0,-3,0,0,R-HSA-425407,SLC-mediated transmembrane transport,M100,1,0
0,1,0,0,-3.4,0,GO:0043300,regulation of leukocyte degranulation,M010,1,0
0,1,0,0,-2.1,0,GO:0070661,leukocyte proliferation,M010,1,0
0,1,0,0,-3.4,0,GO:0045586,regulation of gamma-delta T cell differentiation,M010,1,0
0,1,0,0,-2.1,0,R-HSA-195253,Degradation of beta-catenin by the destruction complex,M010,1,0
0,0,1,0,0,-3.2,GO:0070085,glycosylation,M001,1,0
1,0,0,-4.4,0,0,GO:0006979,response to oxidative stress,M100,1,0
0,1,0,0,-2.5,0,GO:0051046,regulation of secretion,M010,1,0
0,1,0,0,-2.2,0,GO:0032715,negative regulation of interleukin-6 production,M010,1,0
1,0,0,-2.4,0,0,WP5198,Inflammatory bowel disease signaling,M100,1,0
1,0,0,-2.7,0,0,GO:0001961,positive regulation of cytokine-mediated signaling pathway,M100,1,0
0,1,0,0,-2.9,0,R-HSA-2871796,FCERI mediated MAPK activation,M010,1,0
0,1,0,0,-2.3,0,GO:0043068,positive regulation of programmed cell death,M010,1,0
0,1,0,0,-2.3,0,GO:0031663,lipopolysaccharide-mediated signaling pathway,M010,1,0
0,1,0,0,-4.2,0,GO:0032103,positive regulation of response to external stimulus,M010,1,0
0,1,0,0,-2.5,0,GO:0032787,monocarboxylic acid metabolic process,M010,1,0
1,0,0,-2.1,0,0,GO:0001541,ovarian follicle development,M100,1,0
1,0,0,-4.2,0,0,GO:0035710,"CD4-positive, alpha-beta T cell activation",M100,1,0
1,0,0,-2.3,0,0,WP2261,Glioblastoma signaling pathways,M100,1,0
1,0,0,-2.4,0,0,WP5422,IL 19 signaling pathway map,M100,1,0
1,0,0,-2.2,0,0,GO:0009896,positive regulation of catabolic process,M100,1,0
1,0,0,-2.1,0,0,WP2870,Extracellular vesicle mediated signaling in recipient cells,M100,1,0
0,1,0,0,-2.3,0,GO:0002532,production of molecular mediator involved in inflammatory response,M010,1,0
1,0,0,-2,0,0,GO:0002478,antigen processing and presentation of exogenous peptide antigen,M100,1,0
0,1,0,0,-2.4,0,GO:0030224,monocyte differentiation,M010,1,0
0,1,0,0,-2.7,0,M169,PID INTEGRIN2 PATHWAY,M010,1,0
0,1,0,0,-2.6,0,GO:0022030,telencephalon glial cell migration,M010,1,0
0,0,1,0,0,-2.5,R-HSA-9707616,Heme signaling,M001,1,0
0,1,0,0,-3,0,GO:0018212,peptidyl-tyrosine modification,M010,1,0
0,1,0,0,-2.9,0,GO:0006693,prostaglandin metabolic process,M010,1,0
1,0,0,-2.9,0,0,GO:0070669,response to interleukin-2,M100,1,0
1,0,0,-2,0,0,R-HSA-5683057,MAPK family signaling cascades,M100,1,0
1,0,0,-2.1,0,0,GO:0010712,regulation of collagen metabolic process,M100,1,0
1,0,0,-2.1,0,0,R-HSA-166520,Signaling by NTRKs,M100,1,0
0,1,0,0,-2.5,0,GO:0042531,positive regulation of tyrosine phosphorylation of STAT protein,M010,1,0
1,0,0,-3.5,0,0,WP4146,Macrophage markers,M100,1,0
0,1,0,0,-2.6,0,WP3640,Imatinib and chronic myeloid leukemia,M010,1,0
1,0,0,-6.6,0,0,GO:0098657,import into cell,M100,1,0
1,0,0,-2.9,0,0,R-HSA-2559583,Cellular Senescence,M100,1,0
1,0,0,-5.1,0,0,GO:0048880,sensory system development,M100,1,0
0,1,0,0,-2.4,0,WP2795,Cardiac hypertrophic response,M010,1,0
1,0,0,-2.1,0,0,GO:0060972,left/right pattern formation,M100,1,0
1,0,0,-3.7,0,0,GO:2000515,"negative regulation of CD4-positive, alpha-beta T cell activation",M100,1,0
0,1,0,0,-3,0,GO:0042327,positive regulation of phosphorylation,M010,1,0
1,0,0,-4.1,0,0,GO:0043367,"CD4-positive, alpha-beta T cell differentiation",M100,1,0
1,0,0,-2.2,0,0,GO:0045623,negative regulation of T-helper cell differentiation,M100,1,0
0,1,0,0,-2.2,0,GO:0043030,regulation of macrophage activation,M010,1,0
0,0,1,0,0,-2.6,GO:1903844,regulation of cellular response to transforming growth factor beta stimulus,M001,1,0
1,0,0,-2.7,0,0,GO:0001704,formation of primary germ layer,M100,1,0
1,0,0,-3.4,0,0,GO:0032496,response to lipopolysaccharide,M100,1,0
0,1,0,0,-3.2,0,GO:0043547,positive regulation of GTPase activity,M010,1,0
1,0,0,-2.1,0,0,WP4540,Hippo signaling regulation pathways,M100,1,0
0,1,0,0,-4.3,0,GO:0032656,regulation of interleukin-13 production,M010,1,0
0,1,0,0,-4,0,R-HSA-9013149,RAC1 GTPase cycle,M010,1,0
1,0,0,-3.1,0,0,GO:0050680,negative regulation of epithelial cell proliferation,M100,1,0
1,0,0,-3,0,0,GO:0043535,regulation of blood vessel endothelial cell migration,M100,1,0
0,1,0,0,-3.4,0,R-HSA-2029481,FCGR activation,M010,1,0
0,1,0,0,-2.6,0,GO:0140352,export from cell,M010,1,0
0,1,0,0,-3.5,0,GO:0001911,negative regulation of leukocyte mediated cytotoxicity,M010,1,0
1,0,0,-3.9,0,0,WP4217,Ebola virus infection in host,M100,1,0
0,1,0,0,-2.4,0,GO:0032674,regulation of interleukin-5 production,M010,1,0
0,1,0,0,-2.6,0,GO:0051051,negative regulation of transport,M010,1,0
1,0,0,-2.6,0,0,R-HSA-9671555,Signaling by PDGFR in disease,M100,1,0
0,1,0,0,-2.3,0,GO:0042509,regulation of tyrosine phosphorylation of STAT protein,M010,1,0
1,0,0,-3.1,0,0,GO:0001837,epithelial to mesenchymal transition,M100,1,0
0,1,0,0,-2.3,0,WP5322,CKAP4 signaling pathway map,M010,1,0
1,0,0,-3.9,0,0,WP5373,Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy,M100,1,0
1,0,0,-2.8,0,0,GO:0060872,semicircular canal development,M100,1,0
1,0,0,-4.2,0,0,GO:1900274,regulation of phospholipase C activity,M100,1,0
1,0,0,-7.8,0,0,GO:0007423,sensory organ development,M100,1,0
1,0,0,-2.5,0,0,GO:0035050,embryonic heart tube development,M100,1,0
1,0,0,-3.9,0,0,GO:0045581,negative regulation of T cell differentiation,M100,1,0
1,0,0,-2.7,0,0,WP5115,Network map of SARS CoV 2 signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:1901653,cellular response to peptide,M100,1,0
1,0,0,-2.3,0,0,GO:0007498,mesoderm development,M100,1,0
1,0,0,-3.7,0,0,M206,PID PDGFRA PATHWAY,M100,1,0
0,0,1,0,0,-2.1,GO:0048704,embryonic skeletal system morphogenesis,M001,1,0
1,0,0,-2.4,0,0,GO:0050852,T cell receptor signaling pathway,M100,1,0
1,0,0,-3.6,0,0,WP4666,Hepatitis B infection,M100,1,0
1,0,0,-3,0,0,WP3888,VEGFA VEGFR2 signaling,M100,1,0
1,0,0,-4.4,0,0,M122,PID IL2 1PATHWAY,M100,1,0
0,0,1,0,0,-5.3,R-HSA-8941333,RUNX2 regulates genes involved in differentiation of myeloid cells,M001,1,0
1,0,0,-2.9,0,0,R-HSA-2219528,PI3K/AKT Signaling in Cancer,M100,1,0
1,0,0,-2.9,0,0,R-HSA-9673770,Signaling by PDGFRA extracellular domain mutants,M100,1,0
1,0,0,-4.7,0,0,GO:0007167,enzyme-linked receptor protein signaling pathway,M100,1,0
1,0,0,-3.1,0,0,GO:0060021,roof of mouth development,M100,1,0
1,0,0,-2.9,0,0,GO:0001568,blood vessel development,M100,1,0
1,0,0,-2.5,0,0,R-HSA-198693,AKT phosphorylates targets in the nucleus,M100,1,0
1,0,0,-2.2,0,0,M135,PID IL5 PATHWAY,M100,1,0
0,1,0,0,-5.2,0,GO:0060627,regulation of vesicle-mediated transport,M010,1,0
0,1,0,0,-3.6,0,GO:0042116,macrophage activation,M010,1,0
1,0,0,-2.6,0,0,hsa05216,Thyroid cancer,M100,1,0
0,1,0,0,-2.4,0,WP3612,Photodynamic therapy induced NFE2L2 NRF2 survival signaling,M010,1,0
1,0,0,-2.5,0,0,WP3858,Toll like receptor signaling related to MyD88,M100,1,0
1,0,0,-2.2,0,0,GO:0002071,glandular epithelial cell maturation,M100,1,0
1,0,0,-4.4,0,0,GO:0035162,embryonic hemopoiesis,M100,1,0
0,1,0,0,-3.2,0,GO:0050766,positive regulation of phagocytosis,M010,1,0
0,1,0,0,-2.4,0,GO:0097028,dendritic cell differentiation,M010,1,0
0,0,1,0,0,-2.1,R-HSA-400253,Circadian Clock,M001,1,0
0,1,0,0,-2.3,0,M185,PID ALK1 PATHWAY,M010,1,0
0,1,0,0,-3,0,GO:1903533,regulation of protein targeting,M010,1,0
1,0,0,-3.5,0,0,WP2435,Quercetin and Nf kB AP 1 induced apoptosis,M100,1,0
1,0,0,-3,0,0,hsa05203,Viral carcinogenesis,M100,1,0
0,0,1,0,0,-3.3,GO:0043413,macromolecule glycosylation,M001,1,0
1,0,0,-2.1,0,0,GO:0032740,positive regulation of interleukin-17 production,M100,1,0
1,0,0,-3.2,0,0,GO:0010718,positive regulation of epithelial to mesenchymal transition,M100,1,0
0,1,0,0,-7.5,0,R-HSA-9012999,RHO GTPase cycle,M010,1,0
1,0,0,-2.1,0,0,GO:0009595,detection of biotic stimulus,M100,1,0
1,0,0,-3.2,0,0,GO:0098581,detection of external biotic stimulus,M100,1,0
1,0,0,-2,0,0,GO:0007259,receptor signaling pathway via JAK-STAT,M100,1,0
0,1,0,0,-2.2,0,GO:0019722,calcium-mediated signaling,M010,1,0
0,1,0,0,-3.2,0,GO:1903305,regulation of regulated secretory pathway,M010,1,0
0,1,0,0,-4.1,0,GO:0045058,T cell selection,M010,1,0
0,1,0,0,-3.5,0,R-HSA-9664433,Leishmania parasite growth and survival,M010,1,0
0,1,0,0,-3.8,0,GO:0030032,lamellipodium assembly,M010,1,0
1,0,0,-3.7,0,0,GO:0002460,adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M100,1,0
0,1,0,0,-4.1,0,GO:0051897,positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M010,1,0
0,1,0,0,-2.5,0,GO:0002448,mast cell mediated immunity,M010,1,0
1,0,0,-2.3,0,0,M113,PID NFAT 3PATHWAY,M100,1,0
1,0,0,-3.5,0,0,M166,PID ATF2 PATHWAY,M100,1,0
1,0,0,-3.4,0,0,CORUM:1519,IL6ST-PRKCD-STAT3 complex,M100,1,0
1,0,0,-2.3,0,0,GO:0048565,digestive tract development,M100,1,0
0,1,0,0,-4.3,0,GO:1900015,regulation of cytokine production involved in inflammatory response,M010,1,0
1,0,0,-4.4,0,0,GO:0030540,female genitalia development,M100,1,0
1,0,0,-2.4,0,0,WP4906,3q29 copy number variation syndrome,M100,1,0
0,1,0,0,-2.1,0,GO:0030279,negative regulation of ossification,M010,1,0
1,0,0,-2.3,0,0,WP4136,Fibrin complement receptor 3 signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0090383,phagosome acidification,M100,1,0
1,0,0,-3.5,0,0,GO:1901532,regulation of hematopoietic progenitor cell differentiation,M100,1,0
0,1,0,0,-3.5,0,GO:0009267,cellular response to starvation,M010,1,0
1,0,0,-3,0,0,GO:0090596,sensory organ morphogenesis,M100,1,0
1,0,0,-3.5,0,0,WP2858,Ectoderm differentiation,M100,1,0
0,1,0,0,-2.4,0,GO:0032970,regulation of actin filament-based process,M010,1,0
1,0,0,-2.1,0,0,GO:1901652,response to peptide,M100,1,0
0,1,0,0,-2.4,0,GO:0021543,pallium development,M010,1,0
1,0,0,-3.4,0,0,CORUM:2695,ETS2-FOS-JUN complex,M100,1,0
0,1,0,0,-3.7,0,GO:0043087,regulation of GTPase activity,M010,1,0
1,0,0,-2.6,0,0,GO:0002065,columnar/cuboidal epithelial cell differentiation,M100,1,0
0,0,1,0,0,-2.7,GO:0010976,positive regulation of neuron projection development,M001,1,0
1,0,0,-3.2,0,0,GO:0120163,negative regulation of cold-induced thermogenesis,M100,1,0
1,0,0,-2.1,0,0,WP5074,Kallmann syndrome,M100,1,0
0,1,0,0,-2.3,0,hsa04072,Phospholipase D signaling pathway,M010,1,0
1,0,0,-3.8,0,0,WP4585,Cancer immunotherapy by PD 1 blockade,M100,1,0
1,0,0,-2.3,0,0,GO:0019882,antigen processing and presentation,M100,1,0
0,1,0,0,-2.4,0,GO:0033559,unsaturated fatty acid metabolic process,M010,1,0
1,0,0,-2.4,0,0,R-HSA-201556,Signaling by ALK,M100,1,0
0,1,0,0,-2.9,0,GO:0060491,regulation of cell projection assembly,M010,1,0
1,0,0,-3.2,0,0,GO:0010035,response to inorganic substance,M100,1,0
0,1,0,0,-3.9,0,GO:0006935,chemotaxis,M010,1,0
0,1,0,0,-2.5,0,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M010,1,0
0,1,0,0,-4.5,0,GO:0002861,regulation of inflammatory response to antigenic stimulus,M010,1,0
1,0,0,-2.2,0,0,GO:1902894,negative regulation of miRNA transcription,M100,1,0
0,1,0,0,-3.1,0,GO:0097530,granulocyte migration,M010,1,0
1,0,0,-2.4,0,0,GO:0008542,visual learning,M100,1,0
1,0,0,-2.8,0,0,GO:0048732,gland development,M100,1,0
0,0,1,0,0,-5.3,R-HSA-8939246,RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,M001,1,0
1,0,0,-3.8,0,0,hsa05321,Inflammatory bowel disease,M100,1,0
1,0,0,-2.5,0,0,R-HSA-8985947,Interleukin-9 signaling,M100,1,0
1,0,0,-2.4,0,0,GO:0032732,positive regulation of interleukin-1 production,M100,1,0
1,0,0,-2.1,0,0,GO:0030641,regulation of cellular pH,M100,1,0
0,1,0,0,-4.3,0,R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,M010,1,0
0,1,0,0,-3.3,0,GO:0030595,leukocyte chemotaxis,M010,1,0
0,1,0,0,-2.3,0,GO:0032814,regulation of natural killer cell activation,M010,1,0
0,1,0,0,-2.3,0,GO:0032418,lysosome localization,M010,1,0
0,0,1,0,0,-3.3,GO:0006486,protein glycosylation,M001,1,0
1,0,0,-4.6,0,0,GO:0002287,alpha-beta T cell activation involved in immune response,M100,1,0
0,1,0,0,-2.7,0,GO:0045577,regulation of B cell differentiation,M010,1,0
1,0,0,-2.2,0,0,GO:0001525,angiogenesis,M100,1,0
1,0,0,-2.7,0,0,WP2884,NRF2 pathway,M100,1,0
1,0,0,-2.6,0,0,M182,PID IL3 PATHWAY,M100,1,0
1,0,0,-2.6,0,0,GO:0061458,reproductive system development,M100,1,0
0,1,0,0,-4.1,0,R-HSA-9664422,FCGR3A-mediated phagocytosis,M010,1,0
0,0,1,0,0,-2.2,GO:0035108,limb morphogenesis,M001,1,0
1,0,0,-2.2,0,0,GO:0034377,plasma lipoprotein particle assembly,M100,1,0
1,0,0,-4.7,0,0,GO:0042093,T-helper cell differentiation,M100,1,0
1,0,0,-2.2,0,0,GO:0048752,semicircular canal morphogenesis,M100,1,0
0,1,0,0,-2.8,0,GO:0016310,phosphorylation,M010,1,0
1,0,0,-2.9,0,0,R-HSA-9673767,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",M100,1,0
1,0,0,-2.8,0,0,WP395,IL 4 signaling pathway,M100,1,0
0,0,1,0,0,-2.2,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M001,1,0
0,1,0,0,-2.2,0,GO:0032735,positive regulation of interleukin-12 production,M010,1,0
0,0,1,0,0,-2.1,GO:1903053,regulation of extracellular matrix organization,M001,1,0
0,1,0,0,-2.5,0,GO:1903573,negative regulation of response to endoplasmic reticulum stress,M010,1,0
1,0,0,-2.3,0,0,GO:0051453,regulation of intracellular pH,M100,1,0
1,0,0,-2,0,0,GO:0006511,ubiquitin-dependent protein catabolic process,M100,1,0
0,1,0,0,-6.6,0,hsa04666,Fc gamma R-mediated phagocytosis,M010,1,0
0,1,0,0,-2.5,0,hsa04145,Phagosome,M010,1,0
1,0,0,-2.4,0,0,M161,PID IFNG PATHWAY,M100,1,0
0,1,0,0,-2.4,0,GO:1990858,cellular response to lectin,M010,1,0
0,1,0,0,-2.1,0,M44,PID HIF2PATHWAY,M010,1,0
0,0,1,0,0,-2.2,GO:0016032,viral process,M001,1,0
0,1,0,0,-2.1,0,GO:0042098,T cell proliferation,M010,1,0
1,0,0,-3.3,0,0,WP2895,Differentiation of white and brown adipocyte,M100,1,0
0,1,0,0,-4.3,0,R-HSA-8980692,RHOA GTPase cycle,M010,1,0
0,1,0,0,-2.4,0,WP4206,Hereditary leiomyomatosis and renal cell carcinoma pathway,M010,1,0
0,0,1,0,0,-4.6,WP5224,2q37 copy number variation syndrome,M001,1,0
0,0,1,0,0,-3.3,GO:0009101,glycoprotein biosynthetic process,M001,1,0
1,0,0,-2.3,0,0,M164,PID ERBB1 DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-2.1,0,0,GO:0071300,cellular response to retinoic acid,M100,1,0
0,1,0,0,-3.2,0,GO:0034113,heterotypic cell-cell adhesion,M010,1,0
1,0,0,-3,0,0,GO:0046636,negative regulation of alpha-beta T cell activation,M100,1,0
1,0,0,-3,0,0,GO:0000302,response to reactive oxygen species,M100,1,0
1,0,0,-2.3,0,0,GO:0042472,inner ear morphogenesis,M100,1,0
1,0,0,-4.2,0,0,GO:0062197,cellular response to chemical stress,M100,1,0
0,1,0,0,-4,0,R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,M010,1,0
0,1,0,0,-2.4,0,GO:0046457,prostanoid biosynthetic process,M010,1,0
0,1,0,0,-2.1,0,GO:0042119,neutrophil activation,M010,1,0
1,0,0,-3.1,0,0,WP2853,Endoderm differentiation,M100,1,0
1,0,0,-2.6,0,0,R-HSA-9701898,STAT3 nuclear events downstream of ALK signaling,M100,1,0
1,0,0,-2.7,0,0,GO:0001944,vasculature development,M100,1,0
1,0,0,-2.4,0,0,GO:0010575,positive regulation of vascular endothelial growth factor production,M100,1,0
0,1,0,0,-3.8,0,R-HSA-9674555,Signaling by CSF3 (G-CSF),M010,1,0
1,0,0,-2.6,0,0,GO:0061351,neural precursor cell proliferation,M100,1,0
1,0,0,-2.1,0,0,hsa05224,Breast cancer,M100,1,0
1,0,0,-2.3,0,0,GO:0010574,regulation of vascular endothelial growth factor production,M100,1,0
0,1,0,0,-3.1,0,GO:1905897,regulation of response to endoplasmic reticulum stress,M010,1,0
0,1,0,0,-4,0,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M010,1,0
0,0,1,0,0,-2.6,GO:0048701,embryonic cranial skeleton morphogenesis,M001,1,0
1,0,0,-5.6,0,0,GO:0002262,myeloid cell homeostasis,M100,1,0
0,1,0,0,-2.5,0,GO:0001782,B cell homeostasis,M010,1,0
1,0,0,-3.4,0,0,CORUM:2693,NFAT-JUN-FOS DNA-protein complex,M100,1,0
0,1,0,0,-2.8,0,GO:0110053,regulation of actin filament organization,M010,1,0
0,0,1,0,0,-2.2,R-HSA-157118,Signaling by NOTCH,M001,1,0
1,0,0,-3.5,0,0,GO:0090077,foam cell differentiation,M100,1,0
1,0,0,-4.4,0,0,GO:0002292,T cell differentiation involved in immune response,M100,1,0
1,0,0,-3.5,0,0,M151,PID AR TF PATHWAY,M100,1,0
1,0,0,-4.6,0,0,WP69,T cell receptor signaling pathway,M100,1,0
0,1,0,0,-2.5,0,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M010,1,0
1,0,0,-3.3,0,0,GO:0045620,negative regulation of lymphocyte differentiation,M100,1,0
0,1,0,0,-3.5,0,GO:0071499,cellular response to laminar fluid shear stress,M010,1,0
0,1,0,0,-2.3,0,GO:0021987,cerebral cortex development,M010,1,0
1,0,0,-2.8,0,0,R-HSA-9669938,Signaling by KIT in disease,M100,1,0
1,0,0,-2.3,0,0,M229,PID P38 ALPHA BETA DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-2.2,0,0,GO:0055123,digestive system development,M100,1,0
1,0,0,-4.1,0,0,GO:0048806,genitalia development,M100,1,0
0,1,0,0,-2,0,R-HSA-9013423,RAC3 GTPase cycle,M010,1,0
0,1,0,0,-4.3,0,M33,PID GLYPICAN 1PATHWAY,M010,1,0
1,0,0,-2.1,0,0,WP4262,Breast cancer pathway,M100,1,0
0,1,0,0,-2.6,0,GO:1990266,neutrophil migration,M010,1,0
1,0,0,-2,0,0,WP2018,RANKL RANK signaling pathway,M100,1,0
1,0,0,-2.3,0,0,hsa05220,Chronic myeloid leukemia,M100,1,0
0,1,0,0,-4.2,0,GO:0030100,regulation of endocytosis,M010,1,0
1,0,0,-2.9,0,0,M91,PID TCPTP PATHWAY,M100,1,0
0,1,0,0,-3.2,0,GO:0032743,positive regulation of interleukin-2 production,M010,1,0
0,1,0,0,-3.4,0,GO:0031342,negative regulation of cell killing,M010,1,0
1,0,0,-3.5,0,0,GO:0071219,cellular response to molecule of bacterial origin,M100,1,0
1,0,0,-3,0,0,GO:0071375,cellular response to peptide hormone stimulus,M100,1,0
1,0,0,-2.9,0,0,GO:0038113,interleukin-9-mediated signaling pathway,M100,1,0
1,0,0,-2,0,0,hsa05223,Non-small cell lung cancer,M100,1,0
1,0,0,-4.1,0,0,GO:0010518,positive regulation of phospholipase activity,M100,1,0
1,0,0,-2.1,0,0,hsa05230,Central carbon metabolism in cancer,M100,1,0
0,1,0,0,-2.2,0,GO:0060348,bone development,M010,1,0
0,1,0,0,-2.5,0,hsa05340,Primary immunodeficiency,M010,1,0
0,1,0,0,-2,0,GO:2000146,negative regulation of cell motility,M010,1,0
1,0,0,-3.1,0,0,R-HSA-983231,Factors involved in megakaryocyte development and platelet production,M100,1,0
1,0,0,-4.1,0,0,WP428,Wnt signaling,M100,1,0
0,1,0,0,-3.3,0,GO:0045766,positive regulation of angiogenesis,M010,1,0
0,1,0,0,-2.4,0,GO:0003002,regionalization,M010,1,0
1,0,0,-2.5,0,0,GO:0002826,negative regulation of T-helper 1 type immune response,M100,1,0
0,1,0,0,-3.1,0,GO:0032819,positive regulation of natural killer cell proliferation,M010,1,0
1,0,0,-2.3,0,0,GO:0002708,positive regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-2.2,0,0,WP49,IL 2 signaling pathway,M100,1,0
1,0,0,-2.4,0,0,M285,PID HNF3A PATHWAY,M100,1,0
1,0,0,-2.4,0,0,GO:1990869,cellular response to chemokine,M100,1,0
1,0,0,-3.7,0,0,GO:0034599,cellular response to oxidative stress,M100,1,0
0,1,0,0,-2.1,0,GO:0060759,regulation of response to cytokine stimulus,M010,1,0
0,1,0,0,-2.7,0,GO:0002888,positive regulation of myeloid leukocyte mediated immunity,M010,1,0
1,0,0,-4.5,0,0,hsa04010,MAPK signaling pathway,M100,1,0
0,1,0,0,-2.6,0,R-HSA-168898,Toll-like Receptor Cascades,M010,1,0
0,1,0,0,-2.4,0,GO:0071715,icosanoid transport,M010,1,0
1,0,0,-2.7,0,0,GO:0050769,positive regulation of neurogenesis,M100,1,0
0,1,0,0,-2.4,0,M88,PID CD8 TCR PATHWAY,M010,1,0
0,0,1,0,0,-2,GO:0048736,appendage development,M001,1,0
1,0,0,-2.5,0,0,GO:0060390,regulation of SMAD protein signal transduction,M100,1,0
1,0,0,-2.4,0,0,hsa04916,Melanogenesis,M100,1,0
1,0,0,-2.9,0,0,GO:0060041,retina development in camera-type eye,M100,1,0
1,0,0,-2.1,0,0,GO:0051452,intracellular pH reduction,M100,1,0
0,1,0,0,-3.7,0,GO:0060070,canonical Wnt signaling pathway,M010,1,0
0,1,0,0,-3.7,0,GO:0097581,lamellipodium organization,M010,1,0
1,0,0,-3.6,0,0,M28,PID IL4 2PATHWAY,M100,1,0
1,0,0,-2.9,0,0,WP4844,Influence of laminopathies on Wnt signaling,M100,1,0
0,1,0,0,-2.7,0,GO:0032673,regulation of interleukin-4 production,M010,1,0
0,1,0,0,-3.5,0,GO:0045807,positive regulation of endocytosis,M010,1,0
1,0,0,-3,0,0,GO:1902106,negative regulation of leukocyte differentiation,M100,1,0
0,1,0,0,-2.2,0,hsa04926,Relaxin signaling pathway,M010,1,0
1,0,0,-2.6,0,0,hsa04672,Intestinal immune network for IgA production,M100,1,0
1,0,0,-2.9,0,0,GO:1905331,negative regulation of morphogenesis of an epithelium,M100,1,0
1,0,0,-2.1,0,0,GO:0002726,positive regulation of T cell cytokine production,M100,1,0
1,0,0,-5.1,0,0,GO:0002064,epithelial cell development,M100,1,0
0,1,0,0,-5.1,0,M8626,SIG BCR SIGNALING PATHWAY,M010,1,0
1,0,0,-4.6,0,0,GO:0048341,paraxial mesoderm formation,M100,1,0
1,0,0,-2.7,0,0,WP3611,Photodynamic therapy induced AP 1 survival signaling,M100,1,0
0,1,0,0,-2.8,0,GO:0043313,regulation of neutrophil degranulation,M010,1,0
1,0,0,-2.5,0,0,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M100,1,0
0,1,0,0,-2.3,0,GO:0002433,immune response-regulating cell surface receptor signaling pathway involved in phagocytosis,M010,1,0
1,0,0,-2.4,0,0,GO:0030509,BMP signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0033619,membrane protein proteolysis,M100,1,0
1,0,0,-2,0,0,GO:0030856,regulation of epithelial cell differentiation,M100,1,0
1,0,0,-3.3,0,0,GO:1903018,regulation of glycoprotein metabolic process,M100,1,0
0,1,0,0,-3.7,0,GO:0006690,icosanoid metabolic process,M010,1,0
1,0,0,-3.8,0,0,GO:0002831,regulation of response to biotic stimulus,M100,1,0
0,0,1,0,0,-2.6,WP3995,Prion disease pathway,M001,1,0
1,0,0,-4.5,0,0,GO:0006366,transcription by RNA polymerase II,M100,1,0
0,1,0,0,-2.8,0,GO:0032956,regulation of actin cytoskeleton organization,M010,1,0
1,0,0,-4.2,0,0,GO:0043536,positive regulation of blood vessel endothelial cell migration,M100,1,0
1,0,0,-4.5,0,0,GO:0045596,negative regulation of cell differentiation,M100,1,0
1,0,0,-4.5,0,0,R-HSA-8983432,Interleukin-15 signaling,M100,1,0
1,0,0,-3.5,0,0,GO:0048340,paraxial mesoderm morphogenesis,M100,1,0
0,1,0,0,-2.8,0,GO:0097529,myeloid leukocyte migration,M010,1,0
1,0,0,-4.1,0,0,M162,PID RXR VDR PATHWAY,M100,1,0
1,0,0,-7.2,0,0,M290,PID IL12 STAT4 PATHWAY,M100,1,0
1,0,0,-2,0,0,GO:0071453,cellular response to oxygen levels,M100,1,0
0,1,0,0,-4.1,0,GO:0006468,protein phosphorylation,M010,1,0
0,1,0,0,-3.1,0,GO:0030833,regulation of actin filament polymerization,M010,1,0
1,0,0,-2.7,0,0,WP364,IL6 signaling pathway,M100,1,0
0,1,0,0,-2.1,0,GO:0022029,telencephalon cell migration,M010,1,0
1,0,0,-3,0,0,GO:0002066,columnar/cuboidal epithelial cell development,M100,1,0
1,0,0,-2.6,0,0,GO:0021700,developmental maturation,M100,1,0
1,0,0,-2.2,0,0,R-HSA-5607763,CLEC7A (Dectin-1) induces NFAT activation,M100,1,0
1,0,0,-2.2,0,0,GO:1902338,negative regulation of apoptotic process involved in morphogenesis,M100,1,0
1,0,0,-4,0,0,hsa04920,Adipocytokine signaling pathway,M100,1,0
1,0,0,-2,0,0,GO:0070482,response to oxygen levels,M100,1,0
1,0,0,-2.4,0,0,R-HSA-5619507,Activation of HOX genes during differentiation,M100,1,0
0,1,0,0,-3.4,0,GO:0031669,cellular response to nutrient levels,M010,1,0
1,0,0,-2.8,0,0,GO:0010714,positive regulation of collagen metabolic process,M100,1,0
0,1,0,0,-3.1,0,GO:0032645,regulation of granulocyte macrophage colony-stimulating factor production,M010,1,0
0,1,0,0,-2.5,0,hsa05135,Yersinia infection,M010,1,0
1,0,0,-2.1,0,0,GO:0045063,T-helper 1 cell differentiation,M100,1,0
1,0,0,-2.5,0,0,GO:0001503,ossification,M100,1,0
0,1,0,0,-4.6,0,GO:0032722,positive regulation of chemokine production,M010,1,0
0,1,0,0,-2.1,0,GO:0032816,positive regulation of natural killer cell activation,M010,1,0
1,0,0,-2.7,0,0,GO:0051101,regulation of DNA binding,M100,1,0
1,0,0,-2.8,0,0,GO:0032479,regulation of type I interferon production,M100,1,0
0,1,0,0,-3.2,0,WP516,Hypertrophy model,M010,1,0
0,1,0,0,-3.1,0,GO:0045060,negative thymic T cell selection,M010,1,0
0,1,0,0,-2.4,0,WP167,Eicosanoid synthesis,M010,1,0
0,1,0,0,-4.3,0,GO:0051336,regulation of hydrolase activity,M010,1,0
0,1,0,0,-2.1,0,GO:0043368,positive T cell selection,M010,1,0
1,0,0,-2.1,0,0,WP5083,Neuroinflammation and glutamatergic signaling,M100,1,0
1,0,0,-4.3,0,0,GO:0043009,chordate embryonic development,M100,1,0
0,1,0,0,-3,0,hsa05130,Pathogenic Escherichia coli infection,M010,1,0
0,1,0,0,-6.8,0,R-HSA-912631,Regulation of signaling by CBL,M010,1,0
0,1,0,0,-2.8,0,GO:0032817,regulation of natural killer cell proliferation,M010,1,0
1,0,0,-2.7,0,0,WP299,Nuclear receptors in lipid metabolism and toxicity,M100,1,0
1,0,0,-2.1,0,0,GO:0048339,paraxial mesoderm development,M100,1,0
1,0,0,-3.3,0,0,GO:0042088,T-helper 1 type immune response,M100,1,0
1,0,0,-3.2,0,0,GO:0032526,response to retinoic acid,M100,1,0
0,1,0,0,-2.2,0,GO:0032271,regulation of protein polymerization,M010,1,0
1,0,0,-3.7,0,0,hsa05161,Hepatitis B,M100,1,0
1,0,0,-2.8,0,0,GO:0032967,positive regulation of collagen biosynthetic process,M100,1,0
0,1,0,0,-2.7,0,GO:1905898,positive regulation of response to endoplasmic reticulum stress,M010,1,0
1,0,0,-2.4,0,0,GO:0032965,regulation of collagen biosynthetic process,M100,1,0
1,0,0,-3,0,0,WP710,DNA damage response only ATM dependent,M100,1,0
0,1,0,0,-2.4,0,GO:0002223,stimulatory C-type lectin receptor signaling pathway,M010,1,0
1,0,0,-2.4,0,0,WP2875,Constitutive androstane receptor pathway,M100,1,0
1,0,0,-4.4,0,0,WP236,Adipogenesis,M100,1,0
0,1,0,0,-3,0,GO:0030852,regulation of granulocyte differentiation,M010,1,0
0,1,0,0,-2.1,0,WP185,Integrin mediated cell adhesion,M010,1,0
0,0,1,0,0,-2.3,GO:1901137,carbohydrate derivative biosynthetic process,M001,1,0
1,0,0,-4.4,0,0,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M100,1,0
0,1,0,0,-2.6,0,M71,PID ILK PATHWAY,M010,1,0
0,1,0,0,-2.3,0,GO:0045579,positive regulation of B cell differentiation,M010,1,0
0,1,0,0,-2.7,0,GO:0038094,Fc-gamma receptor signaling pathway,M010,1,0
1,0,0,-3.3,0,0,GO:0048598,embryonic morphogenesis,M100,1,0
1,0,0,-3,0,0,GO:1904748,regulation of apoptotic process involved in development,M100,1,0
1,0,0,-2.6,0,0,GO:0032088,negative regulation of NF-kappaB transcription factor activity,M100,1,0
0,1,0,0,-2.1,0,GO:0001773,myeloid dendritic cell activation,M010,1,0
0,1,0,0,-2.6,0,hsa05213,Endometrial cancer,M010,1,0
1,0,0,-2.5,0,0,GO:0003151,outflow tract morphogenesis,M100,1,0
0,1,0,0,-3.7,0,R-HSA-9013148,CDC42 GTPase cycle,M010,1,0
1,0,0,-2.7,0,0,WP4879,Overlap between signal transduction pathways contributing to LMNA laminopathies,M100,1,0
0,1,0,0,-5.5,0,hsa04662,B cell receptor signaling pathway,M010,1,0
1,0,0,-4.4,0,0,WP3599,Transcription factor regulation in adipogenesis,M100,1,0
1,0,0,-4.7,0,0,M235,PID TCR CALCIUM PATHWAY,M100,1,0
1,0,0,-2.2,0,0,GO:2000648,positive regulation of stem cell proliferation,M100,1,0
0,1,0,0,-3.5,0,GO:0046456,icosanoid biosynthetic process,M010,1,0
0,1,0,0,-2.3,0,GO:0006631,fatty acid metabolic process,M010,1,0
0,1,0,0,-2.6,0,M275,PID ALPHA SYNUCLEIN PATHWAY,M010,1,0
0,1,0,0,-2.6,0,GO:0048934,peripheral nervous system neuron differentiation,M010,1,0
1,0,0,-4.1,0,0,M115,PID REG GR PATHWAY,M100,1,0
0,1,0,0,-3.5,0,R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,M010,1,0
0,1,0,0,-2.6,0,GO:0008064,regulation of actin polymerization or depolymerization,M010,1,0
1,0,0,-2.3,0,0,hsa05418,Fluid shear stress and atherosclerosis,M100,1,0
1,0,0,-2,0,0,GO:0002221,pattern recognition receptor signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0051592,response to calcium ion,M100,1,0
0,0,1,0,0,-2.5,GO:0090287,regulation of cellular response to growth factor stimulus,M001,1,0
1,0,0,-2.1,0,0,R-HSA-380994,ATF4 activates genes in response to endoplasmic reticulum  stress,M100,1,0
1,0,0,-2.9,0,0,GO:0014013,regulation of gliogenesis,M100,1,0
1,0,0,-4.1,0,0,WP3972,PDGFR beta pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0071383,cellular response to steroid hormone stimulus,M100,1,0
0,1,0,0,-2.8,0,GO:0030854,positive regulation of granulocyte differentiation,M010,1,0
1,0,0,-2.3,0,0,GO:0007632,visual behavior,M100,1,0
1,0,0,-2.8,0,0,WP4337,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,M100,1,0
0,0,1,0,0,-2.7,R-HSA-1912422,Pre-NOTCH Expression and Processing,M001,1,0
0,0,1,0,0,-2,GO:0060173,limb development,M001,1,0
0,1,0,0,-2.1,0,GO:0048259,regulation of receptor-mediated endocytosis,M010,1,0
1,0,0,-4.7,0,0,GO:0002761,regulation of myeloid leukocyte differentiation,M100,1,0
0,1,0,0,-2.2,0,GO:1903530,regulation of secretion by cell,M010,1,0
1,0,0,-2.4,0,0,WP1528,Physiological and pathological hypertrophy of the heart,M100,1,0
0,1,0,0,-2.4,0,GO:0002260,lymphocyte homeostasis,M010,1,0
0,1,0,0,-2.2,0,GO:0032940,secretion by cell,M010,1,0
1,0,0,-2.6,0,0,GO:0043401,steroid hormone mediated signaling pathway,M100,1,0
0,1,0,0,-4.4,0,WP3937,Microglia pathogen phagocytosis pathway,M010,1,0
1,0,0,-2.8,0,0,GO:1903707,negative regulation of hemopoiesis,M100,1,0
0,0,1,0,0,-3.3,GO:0090162,establishment of epithelial cell polarity,M001,1,0
1,0,0,-3.9,0,0,GO:0022408,negative regulation of cell-cell adhesion,M100,1,0
1,0,0,-3.4,0,0,GO:0071216,cellular response to biotic stimulus,M100,1,0
0,1,0,0,-2.3,0,GO:2000060,positive regulation of ubiquitin-dependent protein catabolic process,M010,1,0
1,0,0,-3,0,0,WP2355,Corticotropin releasing hormone signaling pathway,M100,1,0
1,0,0,-2.6,0,0,GO:0060561,apoptotic process involved in morphogenesis,M100,1,0
0,1,0,0,-3.4,0,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M010,1,0
0,1,0,0,-3.4,0,GO:0033077,T cell differentiation in thymus,M010,1,0
1,0,0,-4,0,0,GO:0046632,alpha-beta T cell differentiation,M100,1,0
1,0,0,-2.8,0,0,R-HSA-383280,Nuclear Receptor transcription pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0048002,antigen processing and presentation of peptide antigen,M100,1,0
0,1,0,0,-2.9,0,M210,PID IL8 CXCR2 PATHWAY,M010,1,0
0,1,0,0,-3,0,GO:1904994,regulation of leukocyte adhesion to vascular endothelial cell,M010,1,0
0,1,0,0,-3.1,0,GO:0001934,positive regulation of protein phosphorylation,M010,1,0
0,0,1,0,0,-3.1,WP4808,Endochondral ossification with skeletal dysplasias,M001,1,0
1,0,0,-2.5,0,0,GO:0007548,sex differentiation,M100,1,0
0,1,0,0,-2,0,GO:0038093,Fc receptor signaling pathway,M010,1,0
0,1,0,0,-2.4,0,R-HSA-2173791,TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),M010,1,0
0,1,0,0,-2.2,0,GO:0021799,cerebral cortex radially oriented cell migration,M010,1,0
1,0,0,-4.5,0,0,GO:0043433,negative regulation of DNA-binding transcription factor activity,M100,1,0
0,1,0,0,-3.9,0,GO:0032655,regulation of interleukin-12 production,M010,1,0
0,1,0,0,-2,0,GO:0046651,lymphocyte proliferation,M010,1,0
1,0,0,-2.4,0,0,M234,PID IL2 STAT5 PATHWAY,M100,1,0
1,0,0,-2.2,0,0,WP4565,Neural crest cell migration in cancer,M100,1,0
1,0,0,-2.5,0,0,GO:0010038,response to metal ion,M100,1,0
0,1,0,0,-4.1,0,M141,PID PI3KCI PATHWAY,M010,1,0
0,1,0,0,-4,0,GO:0034616,response to laminar fluid shear stress,M010,1,0
1,0,0,-2.7,0,0,GO:1901699,cellular response to nitrogen compound,M100,1,0
1,0,0,-4.9,0,0,GO:0043010,camera-type eye development,M100,1,0
1,0,0,-4.7,0,0,GO:0002294,"CD4-positive, alpha-beta T cell differentiation involved in immune response",M100,1,0
0,1,0,0,-2.6,0,GO:0015908,fatty acid transport,M010,1,0
0,1,0,0,-2.6,0,GO:0043376,"regulation of CD8-positive, alpha-beta T cell differentiation",M010,1,0
1,0,0,-2.2,0,0,M65,PID FRA PATHWAY,M100,1,0
0,1,0,0,-2.4,0,GO:0022604,regulation of cell morphogenesis,M010,1,0
1,0,0,-2,0,0,GO:0010498,proteasomal protein catabolic process,M100,1,0
1,0,0,-2.5,0,0,WP5316,Primary ovarian insufficiency,M100,1,0
1,0,0,-2,0,0,GO:0042269,regulation of natural killer cell mediated cytotoxicity,M100,1,0
0,1,0,0,-2.6,0,hsa05134,Legionellosis,M010,1,0
1,0,0,-3.1,0,0,GO:0030522,intracellular receptor signaling pathway,M100,1,0
0,1,0,0,-2.5,0,hsa04520,Adherens junction,M010,1,0
1,0,0,-2.9,0,0,WP4659,Gastrin signaling pathway,M100,1,0
1,0,0,-2.5,0,0,GO:0002520,immune system development,M100,1,0
1,0,0,-2.5,0,0,GO:0099054,presynapse assembly,M100,1,0
1,0,0,-2.3,0,0,WP2324,AGE RAGE pathway,M100,1,0
0,1,0,0,-4.3,0,R-HSA-6798695,Neutrophil degranulation,M010,1,0
0,1,0,0,-4.1,0,R-HSA-9664407,Parasite infection,M010,1,0
1,0,0,-2.8,0,0,GO:0034121,regulation of toll-like receptor signaling pathway,M100,1,0
1,0,0,-2.5,0,0,WP4329,miRNA role in immune response in sepsis,M100,1,0
0,1,0,0,-4,0,GO:0045588,positive regulation of gamma-delta T cell differentiation,M010,1,0
0,1,0,0,-2.3,0,GO:0045576,mast cell activation,M010,1,0
0,0,1,0,0,-2.2,GO:0035107,appendage morphogenesis,M001,1,0
1,0,0,-2.1,0,0,GO:0001779,natural killer cell differentiation,M100,1,0
1,0,0,-5.4,0,0,GO:0001654,eye development,M100,1,0
1,0,0,-2.4,0,0,GO:0071425,hematopoietic stem cell proliferation,M100,1,0
1,0,0,-3.7,0,0,GO:0071222,cellular response to lipopolysaccharide,M100,1,0
0,1,0,0,-3.2,0,hsa05142,Chagas disease,M010,1,0
0,1,0,0,-2.3,0,WP5356,Disturbed pathways in Duchenne Muscular Dystrophy,M010,1,0
0,1,0,0,-2.6,0,GO:0030890,positive regulation of B cell proliferation,M010,1,0
0,1,0,0,-2.4,0,GO:1990840,response to lectin,M010,1,0
1,0,0,-3.5,0,0,R-HSA-9006925,Intracellular signaling by second messengers,M100,1,0
0,1,0,0,-2.4,0,R-HSA-4641265,Repression of WNT target genes,M010,1,0
1,0,0,-2.2,0,0,GO:2000404,regulation of T cell migration,M100,1,0
1,0,0,-2.5,0,0,GO:0001892,embryonic placenta development,M100,1,0
1,0,0,-2.6,0,0,GO:1902882,regulation of response to oxidative stress,M100,1,0
1,0,0,-2.3,0,0,WP4542,Leukocyte intrinsic Hippo pathway functions,M100,1,0
0,1,0,0,-2.2,0,GO:0071622,regulation of granulocyte chemotaxis,M010,1,0
0,1,0,0,-2.6,0,GO:0019370,leukotriene biosynthetic process,M010,1,0
1,0,0,-2,0,0,GO:0010721,negative regulation of cell development,M100,1,0
1,0,0,-2.1,0,0,GO:0021781,glial cell fate commitment,M100,1,0
1,0,0,-3.2,0,0,R-HSA-1257604,PIP3 activates AKT signaling,M100,1,0
1,0,0,-2.5,0,0,GO:0010717,regulation of epithelial to mesenchymal transition,M100,1,0
1,0,0,-4,0,0,GO:0072091,regulation of stem cell proliferation,M100,1,0
1,0,0,-2.2,0,0,GO:0021859,pyramidal neuron differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0060251,regulation of glial cell proliferation,M100,1,0
0,1,0,0,-5.1,0,R-HSA-9658195,Leishmania infection,M010,1,0
0,1,0,0,-2.1,0,hsa05208,Chemical carcinogenesis - reactive oxygen species,M010,1,0
1,0,0,-2,0,0,R-HSA-186797,Signaling by PDGF,M100,1,0
1,0,0,-3.2,0,0,hsa04310,Wnt signaling pathway,M100,1,0
0,1,0,0,-2.7,0,GO:0051100,negative regulation of binding,M010,1,0
0,1,0,0,-3.7,0,GO:0046640,regulation of alpha-beta T cell proliferation,M010,1,0
0,0,1,0,0,-3.9,GO:0006487,protein N-linked glycosylation,M001,1,0
0,1,0,0,-3.5,0,GO:0071496,cellular response to external stimulus,M010,1,0
1,0,0,-2.4,0,0,GO:0051098,regulation of binding,M100,1,0
1,0,0,-2.4,0,0,GO:0010464,regulation of mesenchymal cell proliferation,M100,1,0
1,0,0,-2.4,0,0,GO:1903902,positive regulation of viral life cycle,M100,1,0
1,0,0,-2.3,0,0,hsa04917,Prolactin signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0043161,proteasome-mediated ubiquitin-dependent protein catabolic process,M100,1,0
1,0,0,-2.2,0,0,GO:0065005,protein-lipid complex assembly,M100,1,0
0,1,0,0,-3.2,0,M252,PID IL8 CXCR1 PATHWAY,M010,1,0
1,0,0,-2.1,0,0,GO:0008286,insulin receptor signaling pathway,M100,1,0
1,0,0,-2.1,0,0,hsa05144,Malaria,M100,1,0
0,1,0,0,-2.1,0,GO:0032653,regulation of interleukin-10 production,M010,1,0
1,0,0,-3.4,0,0,GO:0010559,regulation of glycoprotein biosynthetic process,M100,1,0
1,0,0,-2.2,0,0,WP4564,Neural crest cell migration during development,M100,1,0
0,1,0,0,-3.5,0,GO:0042594,response to starvation,M010,1,0
0,1,0,0,-3,0,GO:0002862,negative regulation of inflammatory response to antigenic stimulus,M010,1,0
1,0,0,-3.4,0,0,M124,PID CXCR4 PATHWAY,M100,1,0
1,0,0,-3.1,0,0,GO:0010634,positive regulation of epithelial cell migration,M100,1,0
1,0,0,-3.1,0,0,GO:0046639,negative regulation of alpha-beta T cell differentiation,M100,1,0
0,1,0,0,-2.3,0,GO:1990849,vacuolar localization,M010,1,0
0,1,0,0,-2.3,0,hsa04810,Regulation of actin cytoskeleton,M010,1,0
0,1,0,0,-2.1,0,GO:0031589,cell-substrate adhesion,M010,1,0
1,0,0,-2.2,0,0,GO:2000554,regulation of T-helper 1 cell cytokine production,M100,1,0
1,0,0,-2.2,0,0,GO:0010640,regulation of platelet-derived growth factor receptor signaling pathway,M100,1,0
1,0,0,-2,0,0,GO:1901222,regulation of non-canonical NF-kappaB signal transduction,M100,1,0
0,1,0,0,-2.9,0,GO:0120032,regulation of plasma membrane bounded cell projection assembly,M010,1,0
0,1,0,0,-3.5,0,GO:1905005,regulation of epithelial to mesenchymal transition involved in endocardial cushion formation,M010,1,0
1,0,0,-3.7,0,0,GO:0035239,tube morphogenesis,M100,1,0
1,0,0,-3.6,0,0,GO:0010517,regulation of phospholipase activity,M100,1,0
1,0,0,-2.2,0,0,WP5397,Vitamin A1 and A5 X pathways,M100,1,0
1,0,0,-4.2,0,0,GO:0008285,negative regulation of cell population proliferation,M100,1,0
0,0,1,0,0,-3.1,R-HSA-446203,Asparagine N-linked glycosylation,M001,1,0
0,1,0,0,-5.1,0,R-HSA-194315,Signaling by Rho GTPases,M010,1,0
1,0,0,-2.6,0,0,GO:0001890,placenta development,M100,1,0
0,1,0,0,-2.8,0,GO:0001771,immunological synapse formation,M010,1,0
0,1,0,0,-2.3,0,GO:0032753,positive regulation of interleukin-4 production,M010,1,0
0,1,0,0,-2,0,GO:0030225,macrophage differentiation,M010,1,0
1,0,0,-2.5,0,0,GO:0034614,cellular response to reactive oxygen species,M100,1,0
1,0,0,-2.3,0,0,GO:0002068,glandular epithelial cell development,M100,1,0
1,0,0,-2.9,0,0,GO:0071355,cellular response to interleukin-9,M100,1,0
0,1,0,0,-3.8,0,GO:0043299,leukocyte degranulation,M010,1,0
0,1,0,0,-2.1,0,GO:0042149,cellular response to glucose starvation,M010,1,0
0,0,1,0,0,-2.2,GO:1904888,cranial skeletal system development,M001,1,0
0,1,0,0,-2.3,0,GO:1902235,regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway,M010,1,0
1,0,0,-2.6,0,0,GO:0048608,reproductive structure development,M100,1,0
0,1,0,0,-2.3,0,GO:0051646,mitochondrion localization,M010,1,0
0,1,0,0,-2.1,0,hsa04014,Ras signaling pathway,M010,1,0
1,0,0,-4.1,0,0,R-HSA-186763,Downstream signal transduction,M100,1,0
1,0,0,-2.1,0,0,GO:0001947,heart looping,M100,1,0
1,0,0,-2.1,0,0,GO:0045953,negative regulation of natural killer cell mediated cytotoxicity,M100,1,0
0,1,0,0,-2.6,0,GO:0048935,peripheral nervous system neuron development,M010,1,0
1,0,0,-3.4,0,0,GO:0071352,cellular response to interleukin-2,M100,1,0
0,1,0,0,-3.9,0,GO:0051056,regulation of small GTPase mediated signal transduction,M010,1,0
0,1,0,0,-2.3,0,GO:0006959,humoral immune response,M010,1,0
1,0,0,-4.3,0,0,GO:0007162,negative regulation of cell adhesion,M100,1,0
1,0,0,-2.6,0,0,R-HSA-2262752,Cellular responses to stress,M100,1,0
1,0,0,-2.9,0,0,hsa04625,C-type lectin receptor signaling pathway,M100,1,0
1,0,0,-2.5,0,0,GO:0060760,positive regulation of response to cytokine stimulus,M100,1,0
1,0,0,-2.3,0,0,GO:0002335,mature B cell differentiation,M100,1,0
1,0,0,-3.8,0,0,hsa05215,Prostate cancer,M100,1,0
0,0,1,0,0,-3.1,R-HSA-8936459,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,M001,1,0
1,0,0,-7.1,0,0,M183,PID IL6 7 PATHWAY,M100,1,0
1,0,0,-2.5,0,0,WP3,Transcriptional activation by NRF2 in response to phytochemicals,M100,1,0
1,0,0,-2.4,0,0,GO:0048332,mesoderm morphogenesis,M100,1,0
1,0,0,-2.8,0,0,GO:0048762,mesenchymal cell differentiation,M100,1,0
1,0,0,-2.6,0,0,WP2814,Mammary gland development pathway Puberty Stage 2 of 4,M100,1,0
1,0,0,-4.5,0,0,GO:0048872,homeostasis of number of cells,M100,1,0
0,0,1,0,0,-2.3,GO:0031333,negative regulation of protein-containing complex assembly,M001,1,0
1,0,0,-3.4,0,0,CORUM:2694,ERG-JUN-FOS DNA-protein complex,M100,1,0
0,1,0,0,-2.7,0,GO:2000516,"positive regulation of CD4-positive, alpha-beta T cell activation",M010,1,0
0,1,0,0,-3.5,0,GO:0002444,myeloid leukocyte mediated immunity,M010,1,0
1,0,0,-4.7,0,0,WP3678,Amplification and expansion of oncogenic pathways as metastatic traits,M100,1,0
1,0,0,-2.5,0,0,CORUM:643,CtBP core complex,M100,1,0
1,0,0,-2.7,0,0,hsa04550,Signaling pathways regulating pluripotency of stem cells,M100,1,0
1,0,0,-2.2,0,0,hsa04932,Non-alcoholic fatty liver disease,M100,1,0
0,1,0,0,-2.3,0,GO:0062043,positive regulation of cardiac epithelial to mesenchymal transition,M010,1,0
1,0,0,-2.9,0,0,GO:0010935,regulation of macrophage cytokine production,M100,1,0
0,1,0,0,-2.6,0,GO:0021801,cerebral cortex radial glia-guided migration,M010,1,0
0,1,0,0,-2.2,0,GO:0002275,myeloid cell activation involved in immune response,M010,1,0
0,1,0,0,-3.2,0,R-HSA-9607240,FLT3 Signaling,M010,1,0
1,0,0,-4.1,0,0,WP313,Hepatocyte growth factor receptor signaling,M100,1,0
0,1,0,0,-3.7,0,GO:0031929,TOR signaling,M010,1,0
1,0,0,-3.7,0,0,GO:0045444,fat cell differentiation,M100,1,0
0,1,0,0,-2.5,0,WP3915,Angiopoietin like protein 8 regulatory pathway,M010,1,0
0,1,0,0,-4.9,0,R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",M010,1,0
1,0,0,-2.3,0,0,GO:0019827,stem cell population maintenance,M100,1,0
0,1,0,0,-3,0,GO:0008360,regulation of cell shape,M010,1,0
1,0,0,-2.2,0,0,GO:0048839,inner ear development,M100,1,0
0,1,0,0,-2.6,0,GO:0098543,detection of other organism,M010,1,0
1,0,0,-3.8,0,0,GO:0046660,female sex differentiation,M100,1,0
1,0,0,-2.6,0,0,GO:0051962,positive regulation of nervous system development,M100,1,0
1,0,0,-2.6,0,0,WP3527,Pre implantation embryo,M100,1,0
1,0,0,-2.1,0,0,WP2064,Neural crest differentiation,M100,1,0
1,0,0,-5.2,0,0,GO:0150063,visual system development,M100,1,0
0,1,0,0,-2.4,0,GO:1900017,positive regulation of cytokine production involved in inflammatory response,M010,1,0
1,0,0,-3.7,0,0,GO:0050767,regulation of neurogenesis,M100,1,0
1,0,0,-2.8,0,0,hsa04620,Toll-like receptor signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:2000556,positive regulation of T-helper 1 cell cytokine production,M100,1,0
0,1,0,0,-3.7,0,GO:0042102,positive regulation of T cell proliferation,M010,1,0
1,0,0,-2.5,0,0,hsa04390,Hippo signaling pathway,M100,1,0
1,0,0,-5.4,0,0,M60,PID NFAT TFPATHWAY,M100,1,0
1,0,0,-2.6,0,0,GO:0071277,cellular response to calcium ion,M100,1,0
0,1,0,0,-2.2,0,GO:0032733,positive regulation of interleukin-10 production,M010,1,0
0,1,0,0,-2.3,0,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,M010,1,0
0,1,0,0,-2.9,0,GO:0045055,regulated exocytosis,M010,1,0
1,0,0,-4.5,0,0,WP2374,Oncostatin M signaling pathway,M100,1,0
1,0,0,-2.3,0,0,WP5236,Markers of kidney cell lineage,M100,1,0
1,0,0,-2.8,0,0,WP4211,Transcriptional cascade regulating adipogenesis,M100,1,0
1,0,0,-3.1,0,0,GO:0070672,response to interleukin-15,M100,1,0
0,1,0,0,-2.6,0,M193,PID NEPHRIN NEPH1 PATHWAY,M010,1,0
1,0,0,-2.9,0,0,R-HSA-9818035,NFE2L2 regulating ER-stress associated genes,M100,1,0
0,1,0,0,-2.4,0,R-HSA-6803157,Antimicrobial peptides,M010,1,0
0,1,0,0,-2.3,0,GO:0090314,positive regulation of protein targeting to membrane,M010,1,0
0,0,1,0,0,-2.2,GO:0043254,regulation of protein-containing complex assembly,M001,1,0
1,0,0,-2.6,0,0,GO:0002758,innate immune response-activating signaling pathway,M100,1,0
0,1,0,0,-3.4,0,hsa04062,Chemokine signaling pathway,M010,1,0
0,1,0,0,-2.7,0,GO:0006691,leukotriene metabolic process,M010,1,0
1,0,0,-2.3,0,0,WP481,Insulin signaling,M100,1,0
0,1,0,0,-3.7,0,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M010,1,0
1,0,0,-5.6,0,0,GO:0032870,cellular response to hormone stimulus,M100,1,0
1,0,0,-2.3,0,0,GO:0007179,transforming growth factor beta receptor signaling pathway,M100,1,0
0,1,0,0,-3.7,0,GO:0046645,positive regulation of gamma-delta T cell activation,M010,1,0
1,0,0,-5.3,0,0,GO:0048568,embryonic organ development,M100,1,0
0,1,0,0,-3.2,0,GO:0046643,regulation of gamma-delta T cell activation,M010,1,0
1,0,0,-3,0,0,GO:0010595,positive regulation of endothelial cell migration,M100,1,0
1,0,0,-2.3,0,0,hsa05145,Toxoplasmosis,M100,1,0
0,1,0,0,-2.9,0,GO:0006692,prostanoid metabolic process,M010,1,0
1,0,0,-2.1,0,0,WP5323,Fatty Acids and Lipoproteins Transport in Hepatocytes,M100,1,0
1,0,0,-2.8,0,0,GO:0060191,regulation of lipase activity,M100,1,0
1,0,0,-2.1,0,0,GO:0070301,cellular response to hydrogen peroxide,M100,1,0
1,0,0,-2,0,0,GO:0090092,regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M100,1,0
0,1,0,0,-3.2,0,WP4223,Ras signaling,M010,1,0
0,1,0,0,-4,0,GO:2001187,"positive regulation of CD8-positive, alpha-beta T cell activation",M010,1,0
0,1,0,0,-2.6,0,WP2879,Farnesoid X receptor pathway,M010,1,0
0,1,0,0,-3.9,0,GO:0042330,taxis,M010,1,0
1,0,0,-3.1,0,0,WP22,IL 9 signaling pathway,M100,1,0
0,1,0,0,-3.4,0,GO:0032736,positive regulation of interleukin-13 production,M010,1,0
1,0,0,-2.3,0,0,WP2328,Allograft rejection,M100,1,0
1,0,0,-2.1,0,0,GO:0050678,regulation of epithelial cell proliferation,M100,1,0
1,0,0,-2.3,0,0,GO:1903034,regulation of response to wounding,M100,1,0
1,0,0,-2.1,0,0,GO:0061371,determination of heart left/right asymmetry,M100,1,0
1,0,0,-2,0,0,GO:0048524,positive regulation of viral process,M100,1,0
1,0,0,-3.9,0,0,WP3953,mRNA protein and metabolite inducation pathway by cyclosporin A,M100,1,0
1,0,0,-2.2,0,0,GO:0045655,regulation of monocyte differentiation,M100,1,0
1,0,0,-2.1,0,0,hsa05320,Autoimmune thyroid disease,M100,1,0
1,0,0,-2.1,0,0,GO:0022612,gland morphogenesis,M100,1,0
1,0,0,-2.4,0,0,R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,M100,1,0
0,1,0,0,-3,0,GO:0031349,positive regulation of defense response,M010,1,0
1,0,0,-2.3,0,0,GO:0030326,embryonic limb morphogenesis,M100,1,0
1,0,0,-3.1,0,0,GO:0002237,response to molecule of bacterial origin,M100,1,0
1,0,0,-2.2,0,0,GO:0030851,granulocyte differentiation,M100,1,0
1,0,0,-2.2,0,0,GO:0007368,determination of left/right symmetry,M100,1,0
1,0,0,-2,0,0,GO:0002724,regulation of T cell cytokine production,M100,1,0
0,1,0,0,-2.6,0,GO:2001185,"regulation of CD8-positive, alpha-beta T cell activation",M010,1,0
1,0,0,-3.6,0,0,GO:0014015,positive regulation of gliogenesis,M100,1,0
1,0,0,-2.4,0,0,GO:1990868,response to chemokine,M100,1,0
1,0,0,-6.2,0,0,GO:0032649,regulation of type II interferon production,M100,1,0
1,0,0,-2.9,0,0,hsa04934,Cushing syndrome,M100,1,0
0,1,0,0,-2.3,0,GO:0046633,alpha-beta T cell proliferation,M010,1,0
0,1,0,0,-3,0,WP4155,Endometrial cancer,M010,1,0
0,1,0,0,-2.2,0,GO:0002090,regulation of receptor internalization,M010,1,0
0,1,0,0,-2.1,0,R-HSA-5688426,Deubiquitination,M010,1,0
1,0,0,-4.7,0,0,WP382,MAPK signaling pathway,M100,1,0
0,1,0,0,-2.1,0,GO:0009914,hormone transport,M010,1,0
1,0,0,-2.8,0,0,M36,PID IL27 PATHWAY,M100,1,0
1,0,0,-2.3,0,0,GO:0035113,embryonic appendage morphogenesis,M100,1,0
0,1,0,0,-3.2,0,hsa04015,Rap1 signaling pathway,M010,1,0
0,1,0,0,-2.9,0,GO:0046847,filopodium assembly,M010,1,0
0,1,0,0,-3.3,0,R-HSA-76002,"Platelet activation, signaling and aggregation",M010,1,0
1,0,0,-7.2,0,0,GO:0032729,positive regulation of type II interferon production,M100,1,0
1,0,0,-2.4,0,0,WP304,Kit receptor signaling pathway,M100,1,0
0,1,0,0,-3.8,0,GO:0050853,B cell receptor signaling pathway,M010,1,0
0,1,0,0,-3.7,0,GO:0051896,regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M010,1,0
0,1,0,0,-2.9,0,hsa03320,PPAR signaling pathway,M010,1,0
1,0,0,-2.2,0,0,GO:0002832,negative regulation of response to biotic stimulus,M100,1,0
1,0,0,-3.5,0,0,GO:0071350,cellular response to interleukin-15,M100,1,0
1,0,0,-3.2,0,0,GO:0062009,secondary palate development,M100,1,0
1,0,0,-2.4,0,0,M175,PID ERBB2 ERBB3 PATHWAY,M100,1,0
1,0,0,-3.9,0,0,GO:0051960,regulation of nervous system development,M100,1,0
0,1,0,0,-2.7,0,M17200,SA B CELL RECEPTOR COMPLEXES,M010,1,0
0,1,0,0,-2.4,0,hsa05140,Leishmaniasis,M010,1,0
1,0,0,-2.8,0,0,R-HSA-9818027,NFE2L2 regulating anti-oxidant/detoxification enzymes,M100,1,0
1,0,0,-3.5,0,0,GO:1903054,negative regulation of extracellular matrix organization,M100,1,0
1,0,0,-2.8,0,0,WP530,Cytokines and inflammatory response,M100,1,0
1,0,0,-3.4,0,0,GO:0060193,positive regulation of lipase activity,M100,1,0
0,1,0,0,-4.3,0,GO:0032642,regulation of chemokine production,M010,1,0
0,1,0,0,-2.1,0,M16,PID INSULIN PATHWAY,M010,1,0
0,1,0,0,-2.3,0,GO:0045730,respiratory burst,M010,1,0
0,1,0,0,-2.1,0,GO:1902903,regulation of supramolecular fiber organization,M010,1,0
0,1,0,0,-3.6,0,GO:0040011,locomotion,M010,1,0
0,0,1,0,0,-4.4,R-HSA-8939243,RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,M001,1,0
1,0,0,-2.5,0,0,GO:0048863,stem cell differentiation,M100,1,0
1,0,0,-2.9,0,0,M100,PID SHP2 PATHWAY,M100,1,0
1,0,0,-2.8,0,0,GO:0071695,anatomical structure maturation,M100,1,0
1,0,0,-2.5,0,0,R-HSA-1266695,Interleukin-7 signaling,M100,1,0
0,1,0,0,-2.1,0,GO:0007565,female pregnancy,M010,1,0
0,1,0,0,-5.5,0,GO:0046635,positive regulation of alpha-beta T cell activation,M010,1,0
1,0,0,-2.9,0,0,GO:0071104,response to interleukin-9,M100,1,0
1,0,0,-3.9,0,0,GO:0048871,multicellular organismal-level homeostasis,M100,1,0
1,0,0,-3.5,0,0,GO:0010742,macrophage derived foam cell differentiation,M100,1,0
0,1,0,0,-2.6,0,GO:0032695,negative regulation of interleukin-12 production,M010,1,0
1,0,0,-3,0,0,GO:0014823,response to activity,M100,1,0
1,0,0,-2.4,0,0,GO:0035307,positive regulation of protein dephosphorylation,M100,1,0
0,1,0,0,-2.6,0,hsa04218,Cellular senescence,M010,1,0
1,0,0,-2.4,0,0,GO:0043434,response to peptide hormone,M100,1,0
0,1,0,0,-2.4,0,M257,PID EPHRINB REV PATHWAY,M010,1,0
0,0,1,0,0,-2.7,GO:0007224,smoothened signaling pathway,M001,1,0
1,0,0,-2.9,0,0,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M100,1,0
0,1,0,0,-2.8,0,GO:0043383,negative T cell selection,M010,1,0
0,1,0,0,-2.3,0,GO:1904996,positive regulation of leukocyte adhesion to vascular endothelial cell,M010,1,0
1,0,0,-3.4,0,0,GO:0038110,interleukin-2-mediated signaling pathway,M100,1,0
0,1,0,0,-2,0,GO:0032943,mononuclear cell proliferation,M010,1,0
1,0,0,-3,0,0,M54,PID IL12 2PATHWAY,M100,1,0
1,0,0,-3.5,0,0,M23,PID WNT NONCANONICAL PATHWAY,M100,1,0
0,1,0,0,-3.1,0,GO:0045059,positive thymic T cell selection,M010,1,0
1,0,0,-2.2,0,0,GO:0015711,organic anion transport,M100,1,0
0,0,1,0,0,-2.1,GO:0010975,regulation of neuron projection development,M001,1,0
0,1,0,0,-3.9,0,GO:0031668,cellular response to extracellular stimulus,M010,1,0
1,0,0,-3.8,0,0,hsa05207,Chemical carcinogenesis - receptor activation,M100,1,0
0,1,0,0,-2.4,0,GO:0002828,regulation of type 2 immune response,M010,1,0
0,1,0,0,-2.2,0,hsa05170,Human immunodeficiency virus 1 infection,M010,1,0
0,1,0,0,-2.4,0,M159,PID AMB2 NEUTROPHILS PATHWAY,M010,1,0
1,0,0,-2.3,0,0,GO:0097035,regulation of membrane lipid distribution,M100,1,0
1,0,0,-3.4,0,0,GO:0043371,"negative regulation of CD4-positive, alpha-beta T cell differentiation",M100,1,0
0,0,1,0,0,-2.1,M279,PID RB 1PATHWAY,M001,1,0
1,0,0,-2.4,0,0,WP2526,PDGF pathway,M100,1,0
1,0,0,-3.2,0,0,GO:0009755,hormone-mediated signaling pathway,M100,1,0
0,1,0,0,-2.2,0,GO:0070201,regulation of establishment of protein localization,M010,1,0
0,1,0,0,-2.2,0,GO:0007159,leukocyte cell-cell adhesion,M010,1,0
1,0,0,-2.6,0,0,GO:0048514,blood vessel morphogenesis,M100,1,0
0,1,0,0,-3.7,0,GO:0046638,positive regulation of alpha-beta T cell differentiation,M010,1,0
0,1,0,0,-3.5,0,GO:0071621,granulocyte chemotaxis,M010,1,0
1,0,0,-2.1,0,0,GO:0002719,negative regulation of cytokine production involved in immune response,M100,1,0
1,0,0,-3.8,0,0,GO:0030855,epithelial cell differentiation,M100,1,0
0,1,0,0,-2.1,0,GO:0042092,type 2 immune response,M010,1,0
1,0,0,-3.9,0,0,CORUM:1372,Rb-tal-1-E2A-Lmo2-Ldb1 complex,M100,1,0
1,0,0,-2.9,0,0,GO:0060685,regulation of prostatic bud formation,M100,1,0
1,0,0,-2.6,0,0,GO:0098727,maintenance of cell number,M100,1,0
1,0,0,-4,0,0,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M100,1,0
0,1,0,0,-2.7,0,hsa05231,Choline metabolism in cancer,M010,1,0
0,1,0,0,-3.7,0,GO:0002830,positive regulation of type 2 immune response,M010,1,0
0,1,0,0,-2.3,0,GO:0038096,Fc-gamma receptor signaling pathway involved in phagocytosis,M010,1,0
0,1,0,0,-2.1,0,GO:0050854,regulation of antigen receptor-mediated signaling pathway,M010,1,0
0,1,0,0,-4.1,0,R-HSA-9664417,Leishmania phagocytosis,M010,1,0
1,0,0,-2.9,0,0,GO:0006491,N-glycan processing,M100,1,0
0,1,0,0,-3.1,0,R-HSA-9664323,FCGR3A-mediated IL10 synthesis,M010,1,0
0,1,0,0,-7.3,0,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M010,1,0
0,1,0,0,-2.6,0,GO:0034405,response to fluid shear stress,M010,1,0
0,1,0,0,-2.1,0,GO:0002707,negative regulation of lymphocyte mediated immunity,M010,1,0
0,1,0,0,-4.7,0,GO:0050764,regulation of phagocytosis,M010,1,0
1,0,0,-4.6,0,0,GO:0002293,alpha-beta T cell differentiation involved in immune response,M100,1,0
1,0,0,-2.5,0,0,GO:0007369,gastrulation,M100,1,0
1,0,0,-2.2,0,0,GO:1902036,regulation of hematopoietic stem cell differentiation,M100,1,0
1,0,0,-2.2,0,0,GO:1901533,negative regulation of hematopoietic progenitor cell differentiation,M100,1,0
1,0,0,-2.5,0,0,WP4331,Neovascularisation processes,M100,1,0
1,0,0,-2.4,0,0,hsa04514,Cell adhesion molecules,M100,1,0
1,0,0,-5.7,0,0,GO:0140467,integrated stress response signaling,M100,1,0
1,0,0,-2.2,0,0,WP3942,PPAR signaling pathway,M100,1,0
0,1,0,0,-2.6,0,GO:0006887,exocytosis,M010,1,0
0,1,0,0,-2.3,0,GO:0071498,cellular response to fluid shear stress,M010,1,0
0,1,0,0,-4.1,0,hsa04611,Platelet activation,M010,1,0
0,1,0,0,-3.4,0,GO:0032663,regulation of interleukin-2 production,M010,1,0
0,1,0,0,-2,0,R-HSA-2426168,Activation of gene expression by SREBF (SREBP),M010,1,0
1,0,0,-3.5,0,0,GO:0035723,interleukin-15-mediated signaling pathway,M100,1,0
1,0,0,-2.2,0,0,WP4357,NRF2 ARE regulation,M100,1,0
1,0,0,-2.1,0,0,M5493,WNT SIGNALING,M100,1,0
0,1,0,0,-2.3,0,GO:0002430,complement receptor mediated signaling pathway,M010,1,0
1,0,0,-3,0,0,GO:0035914,skeletal muscle cell differentiation,M100,1,0
0,1,0,0,-2.1,0,GO:0031401,positive regulation of protein modification process,M010,1,0
1,0,0,-2.9,0,0,GO:0043380,regulation of memory T cell differentiation,M100,1,0
1,0,0,-4.2,0,0,GO:0009792,embryo development ending in birth or egg hatching,M100,1,0
